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Abstract
Background
Research suggests that measurable change in cerebrospinal fluid (CSF) biomarkers occurs years in advance of the
onset of clinical symptoms (Beckett 2010). In this review, we aimed to assess the ability of CSF tau biomarkers (t-tau and p-
tau) and the CSF tau (t-tau or p-tau)/ABeta ratio to enable the detection of Alzheimer’s disease pathology in patients with
mild cognitive impairment (MCI). These biomarkers have been proposed as important in new criteria for Alzheimer's disease
dementia that incorporate biomarker abnormalities.
Objectives
To determine the diagnostic accuracy of 1) CSF t-tau, 2) CSF p-tau, 3) the CSF t-tau/ABeta ratio and 4) the CSF p-tau/ABeta
ratio index tests for detecting people with MCI at baseline who would clinically convert to Alzheimer’s disease dementia or
other forms of dementia at follow-up.
Search methods
The most recent search for this review was performed in January 2013. We searched MEDLINE (OvidSP), Embase
(OvidSP), BIOSIS Previews (Thomson Reuters Web of Science), Web of Science Core Collection, including Conference
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Proceedings Citation Index (Thomson Reuters Web of Science), PsycINFO (OvidSP), and LILACS (BIREME). We searched
specialized sources of diagnostic test accuracy studies and reviews. We checked reference lists of relevant studies and
reviews for additional studies. We contacted researchers for possible relevant but unpublished data. We did not apply any
language or data restriction to the electronic searches. We did not use any methodological filters as a method to restrict the
search overall.
Selection criteria
We selected those studies that had prospectively well-defined cohorts with any accepted definition of MCI and with CSF t-tau
or p-tau and CSF tau (t-tau or p-tau)/ABeta ratio values, documented at or around the time the MCI diagnosis was made. We
also included studies which looked at data from those cohorts retrospectively, and which contained sufficient data to
construct two by two tables expressing those biomarker results by disease status. Moreover, studies were only selected if
they applied a reference standard for Alzheimer's disease dementia diagnosis, for example, the NINCDS-ADRDA or
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.
Data collection and analysis
We screened all titles generated by the electronic database searches. Two review authors independently assessed the
abstracts of all potentially relevant studies, and the full papers for eligibility. Two independent assessors performed data
extraction and quality assessment. Where data allowed, we derived estimates of sensitivity at fixed values of specificity from
the model we fitted to produce the summary receiver operating characteristic (ROC) curve.
Main results
In total, 1282 participants with MCI at baseline were identified in the 15 included studies of which 1172 had analysable data;
430 participants converted to Alzheimer’s disease dementia and 130 participants to other forms of dementia. Follow-up
ranged from less than one year to over four years for some participants, but in the majority of studies was in the range one to
three years.
Conversion to Alzheimer’s disease dementia
The accuracy of the CSF t-tau was evaluated in seven studies (291 cases and 418 non-cases).The sensitivity values ranged
from 51% to 90% while the specificity values ranged from 48% to 88%. At the median specificity of 72%, the estimated
sensitivity was 75% (95% CI 67 to 85), the positive likelihood ratio was 2.72 (95% CI 2.43 to 3.04), and the negative
likelihood ratio was 0.32 (95% CI 0.22 to 0.47).
Six studies (164 cases and 328 non-cases) evaluated the accuracy of the CSF p-tau. The sensitivities were between 40%
and 100% while the specificities were between 22% and 86%. At the median specificity of 47.5%, the estimated sensitivity
was 81% (95% CI: 64 to 91), the positive likelihood ratio was 1.55 (CI 1.31 to 1.84), and the negative likelihood ratio was
0.39 (CI: 0.19 to 0.82).
Five studies (140 cases and 293 non-cases) evaluated the accuracy of the CSF p-tau/ABeta ratio. The sensitivities were
between 80% and 96% while the specificities were between 33% and 95%. We did not conduct a meta-analysis because the
studies were few and small. Only one study reported the accuracy of CSF t-tau/ABeta ratio.
Our findings are based on studies with poor reporting. A significant number of studies had unclear risk of bias for the
reference standard, participant selection and flow and timing domains. According to the assessment of index test domain,
eight of 15 studies were of poor methodological quality.
The accuracy of these CSF biomarkers for ‘other dementias’ had not been investigated in the included primary studies.
Investigation of heterogeneity
The main sources of heterogeneity were thought likely to be reference standards used for the target disorders, sources of
recruitment, participant sampling, index test methodology and aspects of study quality (particularly, inadequate blinding).
We were not able to formally assess the effect of each potential source of heterogeneity as planned, due to the small number
of studies available to be included.
Authors' conclusions
The insufficiency and heterogeneity of research to date primarily leads to a state of uncertainty regarding the value of CSF
testing of t-tau, p-tau or p-tau/ABeta ratio for the diagnosis of Alzheimer's disease in current clinical practice. Particular
attention should be paid to the risk of misdiagnosis and overdiagnosis of dementia (and therefore over-treatment) in clinical
practice. These tests, like other biomarker tests which have been subject to Cochrane DTA reviews, appear to have better
sensitivity than specificity and therefore might have greater utility in ruling out Alzheimer's disease as the aetiology to the
individual's evident cognitive impairment, as opposed to ruling it in. The heterogeneity observed in the few studies awaiting
classification suggests our initial summary will remain valid. However, these tests may have limited clinical value until
uncertainties have been addressed. Future studies with more uniformed approaches to thresholds, analysis and study
conduct may provide a more homogenous estimate than the one that has been available from the included studies we have
identified.
Plain language summary
Proteins in cerebrospinal fluids (CSF) for early prediction of developing Alzheimer’s disease or other dementia
in people with mild cognitive problems
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Background
The numbers of people with dementia and other cognitive problems are increasing globally. A diagnosis of dementia at early
stage is recommended but there is no agreement on the best approach. A range of tests have been developed which
healthcare professionals can use to assess people with poor memory or cognitive impairment. In this review, we have
focused on the cerebrospinal fluid (CSF) diagnostic tests.
Review question
We reviewed the evidence about the accuracy of CSF tests in identifying those people presenting with mild cognitive
impairment (MCI) who would develop Alzheimer’s disease dementia or other forms of dementia over a period of time.
Study characteristics
The evidence is current to January 2013. We included 15 studies containing a total of 1282 participants with MCI. The
majority of studies (n = 9) were published between 2010 and 2013. The remaining six studies were published between 2004
and 2009. All of the included studies were conducted in Europe.
Study sizes varied and ranged from 15 to 231 participants.The mean (range) age of the youngest sample was 64 years (45
to 76) and the mean (standard deviation) age of the oldest sample was 73.4 (6.6) years.
Quality of the evidence
Our findings are based on studies with poor reporting, with a majority of studies at unclear risk of bias due to insufficient
details given on how participants were selected and how the clinical diagnosis of dementia was established. According to the
assessment of how the CSF tests were conducted and analysed, eight of 15 studies were of poor methodological quality.
Key findings
Below is a summary of key findings for the tests:
CSF t-tau test for conversion from MCI to Alzheimer’s disease dementia
The sensitivity values in seven individual studies ranged from 51% to 90% while the specificity values ranged from 48% to
88%. The statistical analysis of those studies showed that, at the fixed specificity of 72%, the estimated sensitivity was 77%,
and, at the prevalence of 37%, the positive predictive value was 62% and the negative predictive value was 84%. Based on
these results, on average 62 out of 100 people with MCI and a positive index test result would convert to Alzheimer's disease
dementia but 38 would not; on average, 84 out of 100 people with MCI and with a negative index test result would not
convert to Alzheimer's disease dementia, but 16 would.
CSF p-tau test for conversion from MCI to Alzheimer’s disease dementia
The sensitivity values in six individual studies ranged from 40% to 100% while the specificity values ranged from 22% to
86%. The statistical analysis of those studies showed that, at the fixed specificity of 48%, the estimated sensitivity was 81%,
and, at the prevalence of 37%, the positive predictive value was 48% and the negative predictive value was 81%. Based on
these results, on average 48 out of 100 people with MCI and with a positive index test result would convert to Alzheimer's
disease dementia, but 52 would not; on average, 81 out of 100 people with MCI with a negative index test result would not
convert to Alzheimer's disease dementia, but 19 would.
We found that the cerebrospinal fluid (CSF) diagnostic test, as a single test, lacks the accuracy to identify those people with
mild cognitive impairment (MCI) who would develop Alzheimer’s disease dementia or other forms of dementia over a period
of time. The data suggested that a negative CSF test, in people with MCI, almost indicates the absence of Alzheimer's
disease as the cause of their clinical symptoms. However, a positive CSF test does not confirm the presence of Alzheimer's
disease as the aetiology (cause) of their clinical symptoms.
There were methodological problems in the included studies that did not allow for a clear answer to the review question. The
main limitations of the review were poor reporting in the included studies, lack of a widely accepted threshold of the CSF
diagnostic tests in people with MCI, variability in length of follow-up, and the marked variation in CSF tests’ accuracy
between the included studies.
Background 
Dementia is a progressive syndrome of global cognitive impairment with resultant functional decline.  In the United
Kingdom (UK), it affects 5% of the population over 65 and 25% of those over 85 (Knapp 2007).  Worldwide, there were
estimated to be 36 million people living with dementia in 2010 (Wilmo 2010), and this will increase to over 115 million
by 2050 (Prince 2013). The greatest increases in prevalence are likely to be seen in the developing regions.  By 2040,
China and its western-Pacific neighbours are predicted to have 26 million people living with dementia (Ferri 2005). 
Dementia encompasses a group of neurodegenerative disorders that are characterised by progressive loss of cognitive
function and ability to perform activities of daily living, that can be accompanied by neuropsychiatric symptoms and
challenging behaviours of varying type and severity.  The underlying pathology is usually degenerative and subtypes of
dementia include Alzheimer’s disease dementia, vascular dementia, dementia with Lewy bodies, and frontotemporal
dementia.  There may be considerable overlap in the clinical and pathological presentations (MRC CFAS 2001),
and there is often coexistence of Alzheimer’s disease dementia, vascular dementia and other causes of neuronal
atrophy (Matthews 2009; Savva 2009). 
Alzheimer’s disease dementia is an incurable, progressive, neurodegenerative condition which accounts for over 50%
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of all dementias, afflicting 5% of men and 6% of women over the age of 60 worldwide (World Health Organization 2010).
Its prevalence increases exponentially with age, with Alzheimer’s dementia affecting fewer than 1% of people aged from
60 to 64 years, but 24% to 33% of those over the age of 85 (Ferri 2005).
There have been over a dozen different definitions used to describe cognitive impairment that is somehow
qualitatively different from so-called ‘normal’ ageing.  The first complaints in people with Alzheimer’s disease
spectrum are often cognitive problems such as problems with planning and judgement, as well as the more
characteristic memory complaints. This may lead to a diagnosis of Mild Cognitive Impairment (MCI) if formal testing
reveals objective evidence of cognitive impairment. It has not been previously mandated which psychometric tests
should be used to objectively define cognitive impairment. However, the objectivity of the cognitive impairment
diagnosis is critical, as it differentiates this population from a group with subjective cognitive impairment, which is
more likely to have a non-neurodegenerative aetiology. MCI is a heterogeneous condition, the diagnosis of which
holds very little prognostic significance. There are four outcomes for those within an MCI population: progression to
Alzheimer’s disease dementia, progression to another dementia, maintaining stable MCI, and recovery.  Currently,
16 different classifications are used to define MCI (Matthews 2008). In this protocol, MCI refers to this extended
definition of MCI or to the clinical criteria defined by Petersen criteria or revised Petersen criteria (Petersen 1999; Petersen
2004; Winbald 2004) or to the Cognitive Dementia Rating (CDR = 0.5) scale (Morris 1993). 
Studies indicate that an annual average of 5% to 15% of people with MCI progress to Alzheimer’s disease dementia
(Petersen 1999; Bruscoli 2004; Mattson 2009; Petersen 2009). This all depends on clinical profile, settings and investigation
for vascular disease. At the present time, there is no clinical method to determine accurately which of those people with MCI
will develop Alzheimer’s disease dementia or other forms of dementia. 
Recent consensus guidelines have been developed, e.g. the second iteration of International Working Group (IWG2)
on 'prodromal dementia', which seeks to improve prognostic accuracy in the prodromal phase of Azheimer's dementia
by the incorporation in criteria of Alzheimer's disease-related biomarkers (Dubois 2014). It is in this context, that reviews
such as this one become especially relevant and timely.
Research suggests that measurable change in proton emission tomography (PET), magnetic resonance (MRI) and
cerebrospinal fluid (CSF) biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010).  In this
review, we aimed to assess the ability of CSF total tau (t-tau), CSF phosphorylated tau (p-tau), the CSF t-tau/ABeta ratio,
and the CSF p-tau/ABeta ratio, to enable the detection of Alzheimer’s dementia and other forms of dementia in people with
MCI. These biomarkers have been chosen as they are considered to be the most intimately expressed biomarkers of the
Alzheimer's disease core pathology; namely, the aggregation and fibrilisation of the amyloid plaque and
hyperphosphorylation of tau. Consequentially, these biomarkers have been proposed as important in new criteria for
Alzheimer's disease dementia that incorporate biomarker abnormalities. PET imaging of amyloid is now approved by both
the FDA and EMA to rule out Alzheimer's disease as the aetiology of MCI, especially in individuals with unusual clinical
presentations. However, manufacturers of these tracers have ongoing 'appropriate use criteria' ongoing post-marketing
studies to learn where these tests have greatest usage and utility for the person's accurate diagnosis. Recent improvements
to CSF sampling and the relatively inexpensive nature of this test compared with PET scanning means that it will remain the
test of choice for documenting CSF protein abnormalities in neurodegenerative disease. Side effects are increasingly rare
but include headache and local reactions at the site of the lumbar puncture. Patients on anticoagulative therapies (except
aspirin) are considered at too high a risk by most practitioners to undergo this procedure for the diagnosis of Alzheimer’s
dementia.
Target condition being diagnosed
In this review, there are two target conditions: i) Alzheimer's disease dementia and ii) other forms of dementia, both of which
were assessed at follow-up.
We compared the index test results obtained at baseline with the results of the reference standard (clinical criteria) obtained
at follow-up (delayed verification of clinical diagnosis). 
Index test(s)
This review is part of a suite of reviews for assessing the accuracy of CSF ABeta (Ritchie 2014), PET Amyloid (Zhang 2014; 
Smailagic 2015), MMSE (Arevalo-Rodriguez 2015), and other index tests in identifying those people with MCI without clinical
onset of dementia, who would develop Alzheimer's disease dementia or other forms of dementia during follow-up. We
planned to consider the following:
Total tau (t-tau) and phosphorylated tau (p-tau) CSF biomarker tests
Tau is a microtubule-associated protein located primarily in neuronal axons. There are six different human isoforms,
each of which has multiple phosphorylation sites. Physiologically tau interacts with tubulin and plays an important role in
the organisation and stabilisation of microtubules. Independent of phosphorylation status, slightly increased levels of
CSF total tau (t-tau) have been associated with ageing, vascular dementia, multiple sclerosis, AIDS dementia, head
injury and tauopathy; significant increases with Creutzfeldt-Jakob disease and meningoencephalitis; and a threefold
increase has been seen in Alzheimer’s disease compared to normal controls (Shoji 2002). A systematic review of
CSF biomarkers for Alzheimer’s disease analysing 41 studies of CSF t-tau, demonstrated a specificity of 90% and
sensitivity of 81% in diagnosing the condition (Blennow 2003).
The p-tau protein also has a number of potential phosphorylation sites (Billingsley 1997) and abnormal hyperphosphorylation
has been shown to be associated with microtubule disruption and the formation of neurofibrillary tangles, dystrophic neurites
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surrounded by neuritic plaques, and neuropil threads, major components of Alzheimer’s disease pathophysiology (see
Mandelkow 1998). A systematic review of 11 studies of CSF p-tau in Alzheimer’s disease indicated a diagnostic
specificity and sensitivity of 92% and 80% respectively (Blennow 2003).
There is great interest around the use of biomarkers and imaging techniques for the prediction of progression from
MCI populations to Alzheimer’s disease dementia and other forms of dementia. The international consortium study
Alzheimer Disease Neuroimaging Initiative (ADNI), performed between 2004 and 2009, has so far been a key
cohort study for predicting the progression from MCI to Alzheimer’s disease using biomarkers, and demonstrated a
sensitivity and specificity of CSF t-tau of 70% and 92% and CSF p-Tau181 of 68% and 73% respectively (Petersen 2010).
T-tau/ABeta ratio and p-tau/ABeta ratio CSF biomarker tests
ABeta is produced mainly by neurons, secreted into the CSF and then cleared through the blood-brain barrier and
degraded by the reticuloendothelial system. ABeta levels are thus regulated in strict equilibrium between the brain, CSF
and blood (Shoji 1992), but, in Alzheimer’s disease patients, ABeta42 forms insoluble amyloid and accumulates as
intracerebral fibrils, resulting in decreased levels of CSF ABeta42 (Shoji 2001).
ABeta in CSF has only modest potential as a test for delayed verification of Alzheimer’s disease (Ritchie 2014), with
meta-analysis of studies being hampered by poor methodological quality (Noel-Storr 2013) and multiple thresholds
being reported between studies (Ritchie 2011).
In 2001, the American Academy of Neurology produced practical guidelines for dementia, including three Class II
or III reports in a systematic review of a combination study of ABeta42 and t-tau CSF levels. The sensitivity and
specificity for diagnosis of Alzheimer’s disease were 85% and 87% (Knopman 2001), supported by the 2001
systematic review revealing 83% to 100% sensitivity and 85% to 95% specificity for the CSF ABeta42 and t-tau
combination assay (Blennow 2003). Again, the ADNI cohort study demonstrated that the t-tau/ABeta42 ratio could
be used to predict conversion from MCI to Alzheimer’s disease dementia, revealing a sensitivity of 86% and
specificity of 85% (Petersen 2010).
Clinical Pathway 
Dementia develops over several years and there is a presumed period when people are asymptomatic, although disease
pathology may have accumulated. Individuals or their relatives may first notice subtle impairments of short-term memory
when the completion of complex tasks such as management of finances or medications becomes increasingly difficult. In the
UK, people usually present to their general practitioner who may then refer them to a specialist following a brief cognitive
test, clinical examination and exclusion of relevant physical illness. The biomarkers may then be administered by a specialist.
There is, however, much regional variability in this, with Spain and Nordic countries favouring CSF sampling in their routine
clinical work-up, whereas other countries, such as the UK, do not. However, many people with dementia do not present until
much later in the disorder and they will, therefore, follow a different pathway to diagnosis, for example, being identified during
an admission to general hospital for a physical illness. Thus, the pathway influences the accuracy of the diagnostic test. The
accuracy of the test will vary with the experience of the administrator, and the accuracy of the subsequent diagnosis will vary
with the history of referrals to the particular healthcare setting. Diagnostic assessment pathways may vary in other countries
and diagnoses may be made by a variety of specialists including psychiatrists, neurologists, and geriatricians.
Role of index test(s)
The sampling of CSF and assay for levels of tau and ABeta could have a role when applied in specialist clinics. Due to the
costs, risks, and complexity of the testing, CSF tests will not be applied in a primary care setting. The roles of these index
tests are as add-on biomarker tests which have been proposed in new research diagnostic criteria to compliment clinical
examination and cognitive tests.
Alternative test(s)
We did not include alternative tests in this review, because there are currently no standard practice tests available for the
diagnosis of dementia. 
Rationale
Recently proposed research diagnostic criteria for ‘prodromal dementia’/’pre-dementia stage’/‘MCI due to Alzheimer's
disease pathology’ and for 'Alzheimer’s disease' and for the 'preclinical states of Alzheimer's disease' (Albert 2011; Dubois
2010; Dubois 2014), incorporate biomarkers based on imaging or CSF measures within the diagnostic rubric. These tests
are core to the criteria, assuming they will improve the specificity of the traditional solely clinical criteria. It is crucial that each
of these biomarkers is assessed for their diagnostic accuracy before they are adopted as routine tests in clinical practice. It is
worth noting that in each of these criteria, a single abnormality in any of the proposed biomarker/imaging tests is considered
sufficient to make a diagnosis of prodromal Alzheimer’s disease dementia.
Underpinning the new criteria is the assumption that if Alzheimer’s disease pathology can be diagnosed at an earlier,
pre-dementia stage, this could open critical windows for interventions that will have a greater likelihood of success in
affecting disease pathways and thereby improving clinical symptoms. Earlier accurate diagnosis will also help people
with pre-dementia cognitive impairment, their families and potential carers make timely plans for the future. Coupled
with appropriate contingency planning, proper recognition of the disease may also help to prevent inappropriate and
potentially harmful admissions to hospital or institutional care (Bourne 2007). In addition, the accurate early identification of a
dementia syndrome may improve opportunities for the use of newly evolving interventions designed to delay or prevent
progression to more debilitating stages of dementia.
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Objectives 
To determine the diagnostic accuracy of 1) CSF t-tau, 2) CSF p-tau, 3) the CSF t-tau/ABeta ratio and 4) the CSF p-tau/ABeta
ratio index tests for detecting people with MCI at baseline who would clinically convert to Alzheimer’s disease dementia or
other forms of dementia at follow-up.
Secondary objectives
To investigate the amount and associations of heterogeneity in the included studies of test accuracy.
We expected heterogeneity to be an important component of the review. We planned to use target population, index test,
target disorder and study quality as a framework for the investigation of heterogeneity.
Methods 
Criteria for considering studies for this review
Types of studies 
We considered longitudinal cohort studies in which index test results were obtained at baseline and the reference standard
results at follow-up (see Index tests; Reference standards). These studies necessarily employ delayed verification of
conversion to dementia and are sometimes labelled as ‘delayed verification cross-sectional studies’ (Bossuyt 2008,;
Knottnerus 2002). This approach recognises the challenges of concurrent application of the reference test and index
test. In reality, the reference standard for dementia is tissue sampling and histological examination, either at post
mortem or from brain biopsy. Brain biopsy is not undertaken in any setting and a post mortem is so distant an event
from the index test being conducted that there is the possibility that disease may have developed in the years after the
index test. The Dementia DTA group chose to use later diagnosis of dementia (using standardised criteria) as
evidence of delayed verification. This methodology has been published by our group (Mason 2010) and also reflects the
approach taken in most of the primary research in this area.
We included nested case-control studies if they incorporated a delayed verification design. We believe this can only occur in
the context of a cohort study, so these studies are invariably diagnostic nested cohort studies. We only included data on
performance of the index test to discriminate between people with MCI who converted to dementia and those who remained
stable from those studies. We did not consider data from healthy controls or any other control group.
Participants
Participants recruited and clinically classified as those with mild cognitive impairment (MCI) at baseline were eligible
for inclusion in this review.  The diagnosis for MCI was established using the Petersen criteria or revised Petersen
criteria (Petersen 1999; Petersen 2004; Winbald 2004) and/or Matthews criteria (Matthews 2008) and/or 'CDR = 0.5' (
Morris 1993). These criteria include: subjective complaints; a decline in memory objectively verified by neuropsychological
testing in combination with a history from the patient; a decline in other cognitive domains; no or minimal impairment of
activities of daily living; and not meeting the criteria for dementia. Therefore, the eligible participants had a number of tests,
e.g. neuropsychological tests for cognitive deficit and checklists for activities of daily living, before study entry. Participants
were defined either as amnestic single domain, amnestic multiple domain, non-amnestic single domain, non-amnestic
multiple domain, or nonspecified MCI participants.
We included participants from secondary and tertiary settings. Although demographic and clinical characteristics of MCI, as
well as sources of recruitment, might differ in those settings, we decided not to limit our review by setting; instead, we
planned to look for variation within and between settings, and examined the potential influence of the setting on diagnostic
performance of the index test in the analyses.
We excluded those studies that included people with MCI possibly caused by: i) a current or history of alcohol/drug abuse; ii)
central nervous system (CNS) trauma (e.g. subdural haematoma), tumour, or infection; iii) other neurological conditions, e.g.
Parkinson’s or Huntington’s diseases.
Because detail of the causes of study dropouts is crucial, and, if such data are missing, the reliability of the conclusions must
be questioned, we planned to take this into consideration.
Index tests
Studies that assessed the accuracy of CSF measurements of CSF t-tau, CSF p-tau, CSF t-tau/ABeta ratio, or CSF p-
tau/ABeta ratio were included.
There are currently no generally accepted standards for the plasma or CSF ABeta test threshold, and therefore it was not
possible to prespecify what constituted a positive or negative result. We used the criteria which were applied in each included
primary study to classify participants as either test positive or test negative.
Measure of index test: t-tau and p-tau and ABeta level in CSF (ng.l-1 or pg.ml-1)
The assays most commonly used were conventional Innogenetics, Ghent, Belgium kit or INNOTEST Phospho-Tau(181) kit
or INNOTEST ABeta42 or INNOTEST the multiplexing INNO-BIA AlzBio3 for CSF.
We did not include a comparator test because there are currently no standard practice tests available for the diagnosis of
dementia. We compared the index tests with a reference standard.
Target conditions
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There were two target conditions in this review:
Alzheimer’s disease dementia (conversion from MCI to Alzheimer’s disease dementia)1.
Any other forms of dementia (conversion from MCI to any other forms of dementia)2.
Reference standards
For the purpose of this review, several definitions of Alzheimer’s disease dementia were acceptable. Included
studies could apply probable or possible NINCDS-ADRDA (National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria (McKhann 1984). The
Diagnostic and Statistical Manual of Mental Disorders (DSM) (DSMIII 1987; DSMIV 1994) and International
Classification of Diseases (ICD) (World Health Organization 2010) definitions for Alzheimer’s disease dementia were also
acceptable. It should be noted that different iterations of these standards may not be directly comparable over time (e.g.
DSM-IIIR versus DSM-IV). Moreover, the validity of the diagnoses may vary with the degree or manner in which the criteria
have been operationalised (e.g. individual clinician versus algorithm versus consensus determination). We planned to
consider all these issues in interpreting the results, using sensitivity analyses as appropriate.
Similarly, differing clinical definitions of other forms of dementias were acceptable.  For Lewy body dementia, the
reference standard is the McKeith criteria (McKeith 1996; McKeith 2005). For frontotemporal dementia, the reference
standard is the Lund criteria (LMG 1994, Neary 1998, Boxer 2005). DSM (DSMIII 1987; DSMIV 1994) and ICD (World
Health Organization 2010) were also acceptable for frontotemporal and vascular dementias.
The time interval over which progression from MCI to Alzheimer’s disease dementia or other forms of dementia happened is
also important. As age is the principal risk factor for Alzheimer's dementia and other forms of dementias, the longer the
duration of follow-up, the more likely the possibility of generating false positive findings for the index test. To this end, no
limits were put on the length of follow-up in the included studies, though this important variable was captured so we could
examine between-study variations. This change reflected an alteration to the original thinking in the published protocol and is
noted in the Differences between protocol and review section of this review.
We planned to segment analyses into separate follow-up periods for the delay in verification: less than one year, one year to
less than two years; two to less than four years; and more than four years. 
Search methods for identification of studies 
Electronic searches 
The main search for this review was performed in January 2013. However, we ran a top-up search in December 2015. We
searched MEDLINE (OvidSP), Embase (OvidSP), BIOSIS Previews (Thomson Reuters Web of Science), Web of Science
Core Collection, including Conference Proceedings Citation Index (Thomson Reuters Web of Science), PsycINFO (OvidSP),
and LILACS (BIREME) (see Appendix 1 for details of the sources searched, the search strategies used, and the number of
hits that were retrieved for the search carried out in January 2013). The results of the top-up search that were carried out in
December 2015 have not yet been fully incorporated into the review (please see Results of the search for more details).
We also requested a search of the Cochrane Register of Diagnostic Test Accuracy Studies (managed by the Cochrane
Renal Group).
We did not apply any language or date restrictions to the electronic searches. We did not use methodological search
filters (collections of terms aimed at reducing the number needed to screen by filtering out irrelevant records and
retaining only those that are relevant) in the main bibliographic databases (MEDLINE, Embase and PsycINFO) as a
single-stranded method to restrict the search overall because available filters have not yet proved sensitive enough
for systematic review searches (Beynon 2013). Instead, we used a multi-stranded approach in order to maximise sensitivity,
including some searches run in parallel, that included specific terms designed to capture diagnostic studies (see search
narrative in Appendix 1)
Searching other resources 
We checked the reference lists of all relevant studies for additional studies. We also conducted searches in the MEDION
database (Meta-analyses van Diagnostisch Onderzoek) at www.mediondatabase.nl, Database of Abstracts of Reviews of
Effects (DARE) at http://www.crd.york.ac.uk/CRDWeb, Health Technology Assessment Database (HTA Database) at
http://www.crd.york.ac.uk/CRDWeb, and Aggressive Research Intelligence Facility (ARIF) database at www.arif.bham.ac.uk
for other related systematic diagnostic accuracy reviews; we searched for systematic reviews of diagnostic studies from the
International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence-based Laboratory Medicine
database (C-EBLM). We checked reference lists of any relevant systematic reviews for additional studies. We also contacted
researchers involved in relevant studies for applicable and usable but unpublished data.
Data collection and analysis 
Selection of studies 
Two researchers (EL and AN-S) screened all titles and abstracts generated by the electronic database searches for
relevance. 
Two researchers (EL and AN-S) independently reviewed the remaining abstracts of selected titles and selected all
potentially-eligible studies for full text review. Four researchers (NS, AN-S, SM and EL ) independently further assessed full
manuscripts against the inclusion criteria (see Criteria for considering studies for this review). Where necessary, a third
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arbitrator (CWR) resolved disagreements that the two researchers could not resolve through discussion.
Where a study included useable data but these were not presented in the published manuscript, we contacted the authors
directly to request further information. If the same data set was presented in more than one paper, we included only the
primary paper.
We detailed the numbers of studies selected at each point in a study flow diagram (Figure 1).
Data extraction and management
We extracted data onto a study-specific form which included the following:
Author, year of publication, and journal.
The index test and assay type used (thresholds used to define positive and negative tests).
The criteria used for clinical definition for the baseline population.
Baseline demographics of the study population (age, gender, apolipoprotein E (ApoE) status, MMSE and clinical setting).
The duration of follow-up (mean, minimum, maximum, and median).
The proportion of participants developing the outcome of interest (Alzheimer's disease dementia using NINCDS-ADRDA
criteria) as well as other forms of dementias where standard criteria were used.
The sensitivity and specificity of the index test in defining Alzheimer's disease dementia (these were used to
back-translate into a 2 x 2 table (Appendix 2)).
Other data relevant for creating 2 x 2 tables (TP = true test positive; FP = false test positive; FN = false test negative; TN =
true test negative) e.g. the number of 'abnormal' and 'normal' tests and baseline variables; the number of disease
'presence' and disease 'absence' at follow-up, as well as through scrutiny of scatter plots.
We also extracted data necessary for the assessment of quality as defined below.
Data extraction was performed independently by two blinded review authors (NS and AN-S). Disagreement in data extraction
was resolved by discussion, with the potential to involve a third author (CWR) as arbitrator, if necessary.
Assessment of methodological quality
Two review authors (NS and AN-S), blinded to each other’s scores, independently performed methodological quality
assessments of each study using the QUADAS-2 tool (Whiting 2011), as recommended by the Cochrane Collaboration.
Disagreement was resolved by further review and discussion with the potential to involve a third author (CWR) as arbitrator,
if necessary.
The tool is made up of four domains: participant selection, index test, reference standard and participant flow.
Each domain was assessed in terms of risk of bias, with the first three domains also considered in terms of
applicability concerns (Quadas-2) (Appendix 3).The components of each of these domains and a rubric which details how
judgments concerning risk of bias are made are detailed in Appendix 4. Certain key areas important for this review regarding
quality assessment were participant selection, index test, and blinding.
We did not use QUADAS-2 data to form a summary quality score. We produced a narrative summary describing numbers of
studies that were found to have high/low/unclear risk of bias, as well as concerns regarding applicability.
Statistical analysis and data synthesis
We evaluated test accuracy according to the target condition. There are no accepted thresholds to define what
constitutes a positive or negative CSF index test for identifying those people with MCI who would convert to
Alzheimer’s disease dementia or other forms of dementia over time. Therefore, the estimates of diagnostic accuracy
reported in primary studies were likely to be based on data-driven threshold selection (Leeflang 2008). We conducted
exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver
operating characteristic (ROC) space. We did not meta-analyse pairs of sensitivity and specificity using the bivariate
model, as originally planned, because the results were not clinically interpretable when studies with mixed thresholds
were included in the analysis. Instead, we fitted HSROC meta-analysis models to estimate summary ROC curves using
SAS (Statistical Analysis Software), version 9.2 (SAS Institute 2011). We derived estimates of sensitivity and
likelihood ratios at a fixed value of specificity (chosen a priori as the median specificity for the studies that were
analysed when fitting the model) from the HSROC models for the illustrative purposes. Confidence intervals for
sensitivity and the likelihood ratios were calculated using the delta method (Davison 2003), using the 'estimate' command
after fitting the HSROC models in SAS. HSROC models were only fitted for analyses where data for 2 x 2 tables were
provided by at least six studies, given the need to estimate five parameters. Where HSROC models were fitted, we
summarised the post-test probability of conversion from MCI to dementia given a positive test result and given a negative
test result for a range of prevalences of conversion (pretest) probabilities. This was done by plotting the post-test probabilities
against the pretest probabilities, calculating the former based on the pretest probabilities and the likelihood ratios estimated
from the HSROC model at the median of the observed specificity values from the included studies. A positive predictive
value (PPV) and a negative predictive value (NPV) were also reported, based on the median prevalence (pretest probability)
of conversion across studies. We caution that these post-test probabilities and PPV and NPV values related to likelihood
ratios for hypothetical values of sensitivity and specificity for which the true threshold value of the index test was not known.
Investigations of heterogeneity
Heterogeneity was investigated through visual examination of forest plots of sensitivities and specificities and through visual
examination of the ROC plot of the raw data. The main sources of heterogeneity were thought likely to be reference
standards used, participant sampling, index test methodology and aspects of study quality (particularly inadequate blinding).
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There were insufficient studies, therefore we did not perform meta-regression (by including each potential source
of heterogeneity as a covariate in the HSROC model) as planned (Differences between protocol and review).
Sensitivity analyses
We planned to investigate the effect of quality items (such as pre-specifying threshold) on the accuracy of index
tests by undertaking sensitivity analyses. Due to the limited number of studies, we did not perform any sensitivity
analyses (Differences between protocol and review)
Assessment of reporting bias
We did not investigate reporting bias because of current uncertainty about how it operates in test accuracy studies and the
interpretation of existing analytical tools such as funnel plots. 
Results 
Results of the search
The total number of records identified by the searches up to January 2013 was 20,446. After de-duplication, a small
team of assessors performed a first assessment of the remaining records. After a second assessment, 255 records
were retained, of which 178 were excluded after assessment performed by two review authors. Seventy-seven
references were identified as possible eligible studies and were assessed for inclusion (Figure 1). Fifteen
papers were included, and 40 were discarded for the following reasons: i) data not suitable for analysis or
insufficient data for creating two by two tables (n = 28) (Characteristics of excluded studies); ii) not a delayed
verification study (n = 2); iii) not MCI participants at baseline (n = 2); iv) unsuitable index test (n = 2); v) reference not
obtained (n = 5). In addition, twenty two papers were identified as multiple publications. One paper was not in English
(Urakami 2004). No extra studies were found through reference checking. We obtained usable data for five papers (Amlien
2013; Galluzzi 2010; Hansson 2006; Visser 2009; Vos 2013) through contacting the authors.
We ran a top-up search in December 2015. The results of this search will be fully incorporated into the review at update.
However, readers may wish to know that this search identified a total of 6314 results. After screening, four new studies were
identified for inclusion within the review (please see Additional Tables: Table 1 for more details). The characteristics of these
four new studies and their heterogeneity were all consistent with the fully incorporated studies.
Included Studies
The Characteristics of included studies table lists the characteristics of the 15 included studies containing a total of
1282 participants with MCI at baseline of whom 1172 had analysable data. Two studies (Buchhave 2012; Hansson 2006)
involved the same cohort. Buchhave 2012 reported the data for the CSF p-tau/ABeta ratio index test from a new follow-up
period.
Study designs were seven prospectively well-defined cohorts of participants with MCI (Buchhave 2012; Fellgiebel 2007; 
Galluzzi 2010; Herukka 2007; Kester 2011; Palmqvist 2012; Vos 2013), six nested case-control studies with a
prospectively defined MCI group (Amlien 2013; Hansson 2006; Koivunen 2008; Monge-Argiles 2011; Parnetti 2012; Visser
2009) and two studies with a retrospectively defined MCI group with longitudinal data (Eckerstrom 2010; Hampel 2004).
A majority of studies (n = 9) were published between 2010 and 2013. The remaining six studies were published from 2004 to
2008. All of the included studies were conducted in Europe (five in Sweden, two in Italy and two in Finland, one in The
Netherland, one in Spain, one in Norway, one in Germany and two were European multi-centre studies). They used one
version or another of the Petersen criteria for MCI. Twelve studies applied NINCDS-ADRDA criteria or NINCDS-ADRDA and
DSM criteria as a reference standard for Alzheimer’s disease dementia. Amlien 2013 used Global Dementia Scale (GDS) &
Research criteria, Fellgiebel 2007 used 'CDR = 1 criteria' and Parnetti 2012 did not specify the reference standard at follow-
up.
Study sizes varied and ranged from 15 (Koivunen 2008) to 231 participants (Vos 2013). Nine papers had included
participants with a mean age of 70 years or under. The mean (range) age of the youngest sample was 64 years (45 to
76) (Amlien 2013) and the mean (SD) age of the oldest sample was 73.4 (6.6) years (Monge-Argiles 2011).
Sampling procedure and APOE ɛ4 gene carriers were poorly reported. Participants were mainly recruited from
university memory clinics (n = 8), while one study did not report sources of recruitment (Koivunen 2008).
Different CSF biomarker level values were used as a threshold in the included studies (Additional tables: Table 2).
The threshold was prespecified in only five studies (Amlien 2013; Herukka 2007; Kester 2011; Koivunen 2008; Vos 2013
). A percentage of converters to Alzheimer’s disease dementia ranged from 22% (Visser 2009) to 56% (Hampel 2004
). CSF index test positivity ranged from 23% (Amlien 2013) to 69% (Vos 2013) . Duration of follow-up was reported
as mean and standard deviation (SD), or median, or range. Most studies had follow-up between 12 and 36 months.
Some participants were followed up for less than one year in three of the included studies (Fellgiebel 2007; Hampel 2004; 
Monge-Argiles 2011), and for more than four years in five of the included studies (Buchhave 2012; Herukka 2007; Palmqvist
2012; Parnetti 2012). Participants in the remaining seven studies (Amlien 2013; Eckerstrom 2010; Galluzzi 2010; Kester
2011; Koivunen 2008; Visser 2009) were followed up from one to three years.
Excluded studies
Twenty-nine studies, nine of which were ADNI studies, were excluded as they failed to meet the inclusion
criteria for participants, index test, target condition, or they didn't have diagnostic accuracy data (Characteristics of excluded
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studies). We contacted the authors of two of the ADNI studies (Landau 2010; Westman 2012) in order to obtain additional
data for creating two by two tables. Further information was not available for the Landau 2010 study at the time this review
was prepared. The author of the Westman 2012 study informed us that the accuracy of combined, not individual, CSF
biomarkers was assessed in their study.
Studies awaiting classifications
The Characteristics of studies awaiting classification table lists the characteristics of four studies which might be
considered for the inclusion in an updated review. The authors of all those studies need to be contacted in order to
obtain missing data/relevant information. Regarding the target condition ‘Conversion from MCI to Alzheimer’s disease’,
provisional data from two studies (Ewers 2012; Leuzy 2015) might be used for the analysis of CSF t-tau; data for the analysis
of CSF p-tau ABeta42/p-tau ratio index tests might be available only from Ewers 2012 and Balasa 2014, respectively.
Additional Tables: Table 1 shows that the percentage of converters to Alzheimer’s disease dementia ranged from 36% to
47%. Duration of follow-up was between 24 and 41 months. Leuzy 2015 did not report duration of follow-up and Ewers 2012
did not report a threshold value. The heterogeneity of results in these four studies was consistent with that observed in the
fully incorporated studies.
Methodological quality of included studies
Methodological quality was assessed using the QUADAS-2 tool (Whiting 2011).
Review authors’ judgements about each methodological quality item for each included study are presented in the
Characteristics of included studies table and Figure 2. The overall methodological quality of included study cohorts is
summarised in Figure 3.
In the participant selection domain, we considered five studies (Eckerstrom 2010; Hampel 2004; Herukka 2007; Kester 2011;
Koivunen 2008) to be at high risk of bias because the participants were not consecutively or randomly enrolled or both
the sampling procedure and exclusion criteria were not described. We stated that all included studies avoided a case-
control design because we only considered data on performance of the index test to discriminate between people with
MCI who converted to dementia and those who remained stable. We considered four studies (Amlien 2013; Buchhave 2012; 
Galluzzi 2010; Hansson 2006) to be at low risk of bias. We considered the remaining six studies to be at unclear risk of bias,
due to poor reporting on sampling procedure or exclusion criteria
In the index test domain, we considered eight studies (Buchhave 2012; Eckerstrom 2010; Fellgiebel 2007; Hampel 2004; 
Hansson 2006; Monge-Argiles 2011; Palmqvist 2012; Parnetti 2012) to be at high risk of bias because the threshold
used was not prespecified and the optimal cutoff level was determined from ROC analyses; therefore, the accuracy of
the CSF biomarkers reported in these studies appeared to be overestimated. We considered two studies (Amlien 2013; 
Galluzzi 2010) to be at unclear risk of bias, due to poor reporting. We considered the remaining five studies to be at low risk
of bias.
In the reference standard domain, we considered nine studies (Amlien 2013; Eckerstrom 2010; Fellgiebel 2007; Galluzzi
2010; Hampel 2004; Kester 2011; Koivunen 2008; Monge-Argiles 2011; Parnetti 2012) to be at unclear risk of bias, mainly
because it was not reported whether clinicians conducting follow-up were aware of initial CSF biomarker analysis results.
Three of those nine studies did not clearly report the reference standards used for diagnosing Alzheimer’s disease dementia.
We were not able to obtain the information about how the reference standard was obtained and by whom, due to poor
reporting. We considered the remaining six studies to be at low risk of bias.
In the flow and timing domain, we judged nine studies (Amlien 2013; Eckerstrom 2010; Fellgiebel 2007; Galluzzi 2010; 
Koivunen 2008; Monge-Argiles 2011; Parnetti 2012; Visser 2009; Vos 2013) to be at unclear risk of bias because not
all participants were included in the analysis and/or the follow-up period was shorter than one year and/or reporting
was poor. We judged three studies (Galluzzi 2010; Hansson 2006; Kester 2011) to be at high risk of bias because a large
number of participants with non-Alzheimer's disease dementia were excluded from the analysis. We considered the
remaining three studies to be at low risk of bias.
For assessment of applicability concerns, for the majority of the studies there was no concern that the included
participants and setting, the conduct and interpretation of the index test, and the target condition (as defined by
the reference standard) in each of the included studies did not match the review question. We judged two studies
(Eckerstrom 2010; Koivunen 2008) to be of unclear applicability because of concerns regarding the participant
characteristics or setting. We also judged four studies (Amlien 2013; Eckerstrom 2010; Fellgiebel 2007; Parnetti 2012) to be
of unclear applicability because of concerns with respect to the reference standard.
It should be noted that the lack of concern about applicability of the three domains mentioned above was based on the
inclusion criteria set in the review, and therefore the judgment about applicability may be overstated.
Findings
The key characteristics of each study are summarised in Additional Tables: Table 2 and Table 3. Included studies used a
range of different thresholds. The number of positive CSF index tests at baseline varied across studies. The summary of
main results for the fifteen included studies is presented in Summary of findings table 1.
CSF t-tau for Alzheimer's disease dementia
Individual study estimates of sensitivity and specificity are shown in Figure 4 for each of the seven studies (291 cases and
418 non-cases) that evaluated Alzheimer’s disease dementia. The sensitivity values ranged from 51% to 90% while the
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specificity values ranged from 48% to 88%. The thresholds used ranged from ≥ 77 to ≥ 500 pg/mL (ng/L).
The summary ROC curve summarising the accuracy of CSF t-tau across the seven studies is shown in Figure 5. Because of
the variation in thresholds, we did not estimate a summary sensitivity and specificity. However, we derived estimates of
sensitivity and likelihood ratios at fixed values of specificity from the HSROC model we fitted to produce the summary ROC
curve. At the median specificity of 72%, the estimated sensitivity was 77% (95% CI 67 to 85), the positive likelihood ratio was
2.72 (95% CI 2.43 to 3.04), and the negative likelihood ratio was 0.32 (95% CI 0.22 to 0.47).
At the median specificity (72%) and the median prevalence of Alzheimer's disease dementia (37%) (pretest probability,
Figure 6), the positive predictive value was 62%, which means on average 62 out of 100 people with MCI and a positive
index test result would convert to Alzheimer's disease dementia, but 38 would not. The negative predictive value of 84%
means that on average 84 out of 100 people with MCI and with a negative index test result would not convert to Alzheimer's
disease dementia, but 16 would.
In a hypothetical cohort of 100 people with MCI taking the CSF t-tau test, there would be on average nine false
negatives (participants who convert but incorrectly tested negative) and 18 false positives (participants who did not
convert but incorrectly tested positive) (Summary of findings table 1).
CSF p-tau for Alzheimer's disease dementia
Six studies (164 cases and 328 non-cases) evaluated the accuracy of CSF p-tau for conversion to Alzheimer’s disease
dementia (Figure 7). The sensitivities were between 40% and 100%, while the specificities were between 22% and 86%. The
thresholds used ranged from ≥ 39 to ≥ 85 pg/mL (ng/L).
Figure 8 shows the summary ROC space. We derived the summary estimates at different points on the fitted HSROC curve.
At the median specificity of 48%, the estimated sensitivity was 81% (95% CI 64 to 91), the positive likelihood ratio was 1.55
(CI 1.31 to 1.84), and the negative likelihood ratio was 0.39 (CI 0.19 to 0.82).
At the median specificity (48%) and the median prevalence of Alzheimer's disease dementia (37%) (pretest probability,
Figure 9), the positive predictive value was 48%, which means on average 48 out of 100 people with MCI and with a positive
index test result would convert to Alzheimer's disease dementia but 52 would not. The negative predictive value of 81%
means that on average 81 out of 100 people with MCI with a negative index test result would not convert to Alzheimer's
disease dementia, but 19 would.
In a hypothetical cohort of 100 people with MCI taking the CSF p-tau test, there would be on average seven false
negatives (participants who convert but incorrectly tested negative) and 33 false positives (participants who did not
convert but incorrectly tested positive) (Summary of findings table 1).
CSF p-tau/ABeta ratio for Alzheimer's disease dementia
Five studies (140 cases and 293 non-cases) evaluated the accuracy of the CSF p-tau/ABeta ratio for conversion to
Alzheimer’s disease dementia (Figure 10). The sensitivities were between 80% and 96%, while the specificities were
between 33% and 95%. We were not able to report the range of thresholds due to different measurements: < 6.6 pg/mL
(ng/L); 0.18; 1074.0; < 9.92. Figure 11 shows the summary ROC space. We did not conduct a meta-analysis because the
studies were few and small.
CSF t-tau/ABeta ratio for Alzheimer's disease dementia
Only two studies (Monge-Argiles 2011; Vos 2013) evaluated the accuracy of the CSF t-tau/ABeta ratio for conversion to
Alzheimer’s disease dementia.The sensitivities were 50% and 51%, and specificities were 91% and 96%, respectively. We
were not able to conduct the meta-analysis.
CSF t-tau for all forms of dementia (combined Alzheimer's disease dementia and non-Alzheimer's disease dementia)
Only four studies (166 cases and 153 non-cases) evaluated the accuracy of CSF t-tau for conversion to all forms of
dementia (Figure 12 and Figure 13). The sensitivity values ranged from 42% to 79%, while the specificity values ranged from
63% to 95%. The thresholds used ranged from ˃ 350 to ≥ 500 pg/mL (ng/L). As above, we did not conduct a meta-analysis
because the studies were few and small.
Investigation of heterogeneity
We were not able to formally assess the effects of each potential source of heterogeneity as planned, due to the small
number of studies available to be included.
Sensitivity analyses
Due to the limited number of studies evaluating each of four CSF biomarkers for Alzheimer’s disease dementia or other types
of dementia, we did not perform any sensitivity analyses, as planned.
Discussion 
We performed a review of the available evidence on the diagnostic accuracy of CSF biomarker levels for detecting
Alzheimer's disease pathology in people with MCI, and identifying those MCI participants who would convert to Alzheimer’s
disease dementia or other forms of dementia over time. In the absence of a contemporaneous reference standard for
Alzheimer's disease diagnosis relative to the application of the index test, the decision to use a delayed verification design
was taken for all DTA reviews by our group. This, however, creates problems when the length of follow-up in studies varies,
as the longer a study, in a chronic disorder where age is the principal risk factor, could create false positive findings. To
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address this, length of follow-up was collected to help interpret between-study variations in accuracy.
There is, however, a paucity of evidence in relation to the accuracy of CSF biomarkers. Where data were available for
conversion to Alzheimer’s disease dementia, there was a wide range of sensitivity (51% to 90%; 40% to 100%; 80% to 96%)
and specificity (48% to 88%; 22% to 86%; 33% to 95%) values for the CSF t-tau, CSF p-tau and CSF p-tau/ABeta ratio index
tests, respectively.
Due to the wide variations in thresholds, we did not estimate a summary sensitivity and specificity. Although, subject to
considerable uncertainty of a statistical approach, in order to illustrate the potential strengths and weaknesses of CSF
biomarker levels we estimated from the fitted summary ROC curve that the sensitivity was 77% (95% CI 67 to 85) and 81%
(95% CI 64 to 91) at the included study median specificity of 72% and 48% for the CSF t-tau and CSF p-tau respectively.
Assuming a conversion rate of MCI to Alzheimer’s dementia of 37%, for every 100 CSF t-tau level, nine individuals with a
negative test would progress and 18 with a positive test would not progress to Alzheimer’s dementia; for every 100 CSF p-
tau level, seven individuals with a negative test would progress and 33 with a positive test would not progress to Alzheimer’s
dementia. The estimation of predictive values and consequences in a cohort of 100 (‘missed cases’ and ‘over-diagnosed’)
were based on hypothetical sensitivity and specificity values for which the threshold of the test is unknown; therefore, these
findings should be interpreted with caution.
We were not able to evaluate the accuracy of CSF biomarkers for conversion from MCI to other forms of
dementia (non-Alzheimer’s disease dementia). As a result of the information available from four studies (Eckerstrom 2010; 
Galluzzi 2010; Hansson 2006; Herukka 2007), we evaluated the accuracy of CSF t-tau for conversion to all types of
dementia (combined Alzheimer's disease dementia and non-Alzheimer’s disease dementia). The sensitivity values ranged
from 42% to 79% while the specificity values ranged from 63% to 95%. We did not conduct a meta-analysis because the
studies were few and small.
Previous reviews of tests of amyloid in CSF and plasma (Ritchie 2014) and evidenced through PET imaging (Zhang 2014)
have been published. They highlighted that as a test, there was consistently better sensitivity than specificity whereby the
absence of evidence of amyloid pathology (low levels in CSF and high levels in the cortices) was likely to exclude a later
diagnosis of Alzheimer's disease dementia, whereas the presence of amyloid pathology did not add much incremental
benefit to diagnostic accuracy. Considering the findings of this systematic review, we have demonstrated again that the NPV
is greater than the PPV which is a reflection of the higher sensitivity of these tests compared to their specificity. That is, a test
indicating absence of biomarker abnormality and hence suggesting absence of disease is of more value than a positive
biomarker indicating disease. CSF biomarkers are better at ruling out Alzheimer’s disease than ruling it in as a cause of the
clinical symptoms, and therein progression to Alzheimer’s dementia in people described as having MCI. However, the
reported optimal thresholds in individual papers tended to yield better sensitivities than specificities and this was reflected in
our sROC analysis; therefore, those results should be interpreted with caution.
Given the insufficient evidence to evaluate the diagnostic value in MCI of CSF t-tau, CSF p-tau and the CSF p-
tau/ABeta ratio for Alzheimer's disease dementia and other dementias examined in this review, particular attention
should be paid to the risk of misdiagnosis and overdiagnosis of dementia (and therefore overtreatment) in clinical
practice. Our findings are consistent with the expert opinion conveyed by Molinuevo et al (Molinuevo 2014) where it was
recognised that negative tests results were more clinically useful than positive ones. They still saw a routine use for these
tests in clinical practice, and our review will help describe the degree of accuracy to help inform clinicians using this test in
their current practice. As sensitivity of this test was better than specificity, the risk of a missed diagnosis, or a false-negative
test was lower. False reassurance given to a patient that they don't have or will not get Alzheimer's dementia would also
have serious clinical consequences; however, appropriate pretest counselling for what can and cannot be revealed through
CSF testing would mitigate the risk of an inappropriate level of salience being afforded to this particular test.
Summary of main results
In total, 1282 participants with MCI at baseline were identified in the fifteen included studies, of which 1172 had analysable
data; 430 participants converted to Alzheimer’s disease dementia and 130 participants to other forms of dementia at follow-
up. It was possible to undertake a summary analysis of the CSF t-tau and p-tau markers but not the ratio, as too few studies
presented results for the ratio. Consistent with the findings from the amyloid reviews, CSF t-tau and p-tau were reasonably
sensitive tests for later diagnosis of Alzheimer's disease dementia, but had poor specificity. This is illustrated in Figure 6 and
Figure 9 where the small positive likelihood ratio for both CSF t-tau and p-tau has very little impact on the change
from pretest probability to post-test probability. With respect to the CSF t-tau/Abeta ratio, it was not possible to
generate likelihood ratios, due to only one study (Monge-Argiles 2011) reporting data . However, from Figure 10, it
can be seen that for all but one study (Parnetti 2012), the sensitivity exceeded the specificity for the p-tau/ABeta ratio. Figure
12 though demonstrates across four studies, that the specificity of CSF t-tau is improved when the outcome is 'all forms of
dementia', suggesting that the elevation of tau is a nonspecific marker of neurodegeneration and not tightly tethered to
Alzheimer's disease pathology.
Our findings were based on studies with poor reporting and most included studies had an unclear risk of bias, mainly for
reference standard and participant selection domains. Nine studies (56%) had unclear risk of bias for the flow and timing
domain, mainly due to not including all participants in the analysis or inappropriate duration of the follow-up period. According
to the assessment of the index test domain, 50% of studies were of poor methodological quality.
The main sources of heterogeneity were thought likely to be index test thresholds, reference standards used for the target
disorders, sources of recruitment, participant sampling and aspects of study quality (particularly inadequate blinding). We
were not able to formally assess the effects of each potential source of heterogeneity, as planned, due to the small number
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of studies available to be included.
Strengths and weaknesses of the review
There were a number of strengths to this review. This review was conducted in adherence to the inclusion criteria and
methods described in a published protocol (Ritchie 2011). We searched a number of electronic databases, using an
extensive range of appropriate database indexing terms and equivalent text words covering the index test, how it was
measured, and the target condition. The multi-stranded search approach that we adopted to combine different search
concepts in searches run in parallel, some including a more specific diagnostic component, has successfully
increased the overall sensitivity of the search and is a strength of this review. Our searches were not limited by
language. We contacted 12 study authors and usable data were obtained for five studies (Amlien 2013; Galluzzi 2010; 
Hansson 2006; Visser 2009; Vos 2013).
There were, however, also a number of limitations to this review. There was limited published information and
substantial variation in the quality of the papers and caution is needed when interpreting these findings. Most included
studies provided little data on participants at baseline. Several studies reported high or unclear dropout and withdrawal
rates. Studies also contained wide variations in thresholds. It is also a weakness of the review that variability in length
of follow-up in the various cohorts was so great. It would stand to reason that a longer follow-up period would more
likely yield more cases of dementia, given that age is the principal risk factor for dementia. On the other hand, short
follow-up periods might increase false negative results. This topic is of great interest to the field where determination of
proximal and distal biomarkers are being considered. In an MCI population presenting to a clinician, it is the question of
proximity to a decline to dementia which is the most relevant; in this regard, follow-up periods of over five years lose
clinical meaningfulness. Standardisation of the follow-up period would help reviews like this; this has been suggested in
our group's recent STARDdem proposals (Noel-Storr 2014). In our review, we were unable to formally test what affect length
of follow-up had on the accuracy of the test. The various contributors to the heterogeneity across the studies may affect the
study results. Given the poor reporting within the included studies, it is difficult to determine the underlying difference or
differences among the included studies. This highlights a shortfall of large-scale, high-quality empirical research conducted in
this area. Future studies should provide clearer reporting of the participants, equipment, usage and the implications of
implementing the tests. As the current research area is rapidly changing, further research exploring the impact of the CSF p-
tau/ABeta ratio on clinical outcomes is needed. To this end, we conducted a very recent literature review which revealed four
new studies that will be fully incorporated in our next planned update. These four studies demonstrated the same between-
study heterogeneity in results and methodology that we had observed in the included studies, with the implication that there
will not be an impact of incorporation on our existing conclusions.
Applicability of findings to the review question
These findings can be considered a reasonable answer to the question being set in this review. Caution, though, should still
apply because of the quality and reporting issues highlighted from the included papers and the small data set. This is
especially true when drawing conclusions from the analysis of the p-tau/ABeta ratio. This is particularly important as it this
ratio that is often favoured in clinical practice as being most accurate. However, this review and the previous published
reviews of amyloid tests and Alzheimer's disease pathology consistently demonstrate reasonable sensitivity and poor
specificity; accordingly, it is likely that the ratio of two sensitive tests will generate greater sensitivity than specificity.
Authors' conclusions 
Implications for practice 
The principal conclusion from our review is that of ongoing uncertainty regarding the true value of these tests in the
management of people with prodromal dementia or MCI.
The use of and access to lumbar punctures (LP) in dementia clinics varies greatly between and within countries. The
test is usually straightforward with only very occasional side effects, such as headache. However, acceptability of an
LP by patients and carers also varies greatly and may reflect the views of the clinicians proposing their use and their
perspective on the value of the test diagnostically. In the context of the new diagnostic criteria being used for
prodromal Alzheimer's dementia (Dubois 2014), the tests studied here have been used as being indicative of
Alzheimer's pathology. The data from this review suggests that a negative CSF test, in people with MCI, is likely to
reflect the absence of Alzheimer's disease pathology as the aetiology of their clinical symptoms. However, in CSF
sampling for ABeta and tau levels, a positive result does very little to indicate the presence of Alzheimer's disease as
the aetiology of their clinical symptoms. In the new National Institute on Aging and Alzheimer Association criteria (Albert
2011), the presence of abnormally high t-tau/p-tau or low ABeta is thought to indicate MCI due to Alzheimer's disease. This
is not supported by this or previous reports. What is more consistent with our findings is that, in the presence of normal levels
of CSF t-tau/p-tau and ABeta, we can say MCI is not due to Alzheimer's disease. This is an important distinction and one that
has important implications when conveying risk of progression to people with MCI, as well as when giving pretest counselling
to people before the test takes place. The positive and negative likelihood ratios we have generated as illustrations of our
findings do demonstrate that positive and negative tests do have a small change from pre- to post-test probability. However,
they are relatively small and way below what would be expected from standard thresholds for a good test. The language
used in new criteria do not reflect this level of uncertainty or small incremental benefit, and therefore confer much greater
diagnostic accuracy on these tests than is currently merited. Our review suggests that where these tests are used to assist
clinical diagnosis, their limitations and low incremental benefit should be considered. In the absence currently of any disease
modifying interventions, the risk of overdiagnosis to a patient may do greater harm than underdiagnosis. However, this is a
rapidly moving field and if disease-modifying or secondary prevention interventions become available, then this opinion will
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shift, more so if the interventions are effective, low cost and well tolerated.
Implications for research 
These tests though still have value in clinical trials with drugs proposed to affect the Alzheimer's disease
process where normal levels should be used to exclude subjects from the trial with the knowledge that
many individuals with 'positive' tests who are entered in to the study will still not progress to Alzheimer's
disease dementia. Moreover, there may well be an interaction between test results, diagnosis, and stage
of illness. For instance, abnormalities in these tests may be more specific if noted in younger people with
no or minimal symptoms as opposed to older, symptomatic people where they may be reflections of
nonspecific neurodegeneration, ageing or physiological reactions to ABeta oligomerisation (plaque
formation). Only by undertaking longitudinal studies in mid-life, preclinical populations can we answer that
proposition; these types of studies are ongoing. It is also the case that several initiatives to collate data
from across numerous cohort studies are commencing. These include Dementia Platform UK and the IMI-
funded European Medicines Informatic Framework (EMIF) (http://www.emif.eu; http://www.dementiasplatform.uk) and
European Prevention of Alzheimer's Dementia (EPAD) (Ritchie 2016) programme that will deliver analyses of source-
aggregated data that will, in most cases, have been collected under standardised conditions, as well as (in the case of
EPAD) developing a new longitudinal cohort which will provide at least ten-fold increase in sample size for
predementia disease modelling (Ritchie 2016). New cohort data are also being regularly published, especially as extant
cohorts undergo further assessments. Together this suggests that as a rapidly moving field, this review will need to be
updated on a regular basis and will include data from preclinical (asymptomatic) as well as MCI populations.
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Published notes 
Characteristics of studies
Characteristics of included studies 
Amlien 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: nested case-control study with a
delayed verification design
Prospective MCI group of 49 participants with
MCI, who attended a university-based memory
clinic, was recruited consecutively between
2005 and 2009. Twenty-three control subjects
were also recruited. We only included data on
performance of the index test to discriminate
between participants with MCI who converted to
dementia and those who remained stable.
Exclusion criteria: psychiatric disorder, anoxic
brain damage, cancer, drug abuse, or cognitive
symptoms related to solvent exposure.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
39 MCI participants diagnosed by the
Petersen 1991 criteria were included in the
analysis. Ten MCI participants did not have a
follow-up assessment.
GENDER: 20 men; 19 women
AGE (y): MCI with abnormal CSF t-tau level:
64 (range 45 to 76); MC with normal CSF t-
tau level: 58.5 (45 to 77)
APOE ε4 carrier (%): not reported
MMSE: MCI with abnormal CSF t-tau level:
27.2 (range 25 to 29); MC with normal CSF t-
tau level: 27.9 (23 to 30)
Education (y): MCI with abnormal CSF t-tau
level: 12.2 (range 7 to 18); MC with normal
CSF t-tau level: 11.8 (8 to 16)
Sources of referral: not reported
Sources of recruitment: a university-based
memory clinic, Oslo, Norway.
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
CSF t-tau
Participants underwent lumbar puncture as part of the clinical evaluation. The CSF samples were
examined for total tau levels with commercially available kits (Innogenetics, Ghent, Belgium).
Threshold: This was prespecified. The age-dependent criteria for pathologic values were based on a
large sample of healthy control subjects and were as follows: total tau of 300 ng/L or higher for age
younger than 50 years, total tau of 450 ng/L or higher for age 50 to 69 years, and total tau of 500 ng/L
or higher for age older than 70 years (Sjogren 2001). The 0.90 fractile was estimated to establish
reference values for CSF t-tau.
Not reported whether the index test results were interpreted without knowledge of the results of the
reference standard.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: The Global
Deterioration Scale (Reisberg 1982) in
combination with the research criteria
for the diagnosis of Alzheimer's
disease, International Working group (Dubois
2007)
Not reported whether clinicians conducting
follow-up were aware of CSF t-tau results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: mean 2.6 ± 0.54 years
At baseline: 49 MCI participants had CSF sample
At follow-up: 39 participants: 9 MCI with abnormal
baseline CF t-tau: 5 MCI converters and 4 MCI
nonconverters; 30 MCI with normal baseline CSF t-
tau: 4 MCI converters and 26 MCI nonconverters
(information from the author)
Number included in analysis (N=39)
Conversion to ADD:
TP = 5; FP = 4; FN = 4; TN = 26
sensitivity = 55%; specificity = 87% (calculated in
Revman5)
Loss to follow-up
N = 17 participants (10 MCI and 7 controls) did not
have a follow-up assessment. Between baseline
and follow-up, four participants with MCI objected
to re-examination, one died of unrelated causes,
and five were excluded because of definite other
diagnoses. Seven control subjects objected to re-
examination. All 39 MCI participants with the
follow-up assessment were included in the analysis
(page 297).
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes The trial investigators contacted; they provided relevant data for creating 2 X 2 table
(email on 13/12/13).
 
Buchhave 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: prospective cohort study
The inclusion of 137 participants was described
in the paper by Hansson 2006, as below:
180 participants with MCI, who had sought
medical advice for subjective memory
difficulties, were consecutively recruited at a
university hospital between July 1998 and June.
Thirty-six healthy controls were also included,
but appeared to have been used for comparison
purposes only and not included in the ROC
analysis. CSF was obtained at baseline from
137 MCI participants. Of the 43 participants with
MCI who did not undergo successful lumbar
puncture at baseline, 32 preferred not to go
through the procedure and in 11 the procedure
did not deliver usable CSF.
Participants with other causes of cognitive
impairment, including brain tumour, subdural
haematoma, CNS infection, and current alcohol
abuse, were excluded.
Buchhave 2012 and Hansson 2006 studies
used the same cohort.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
137 participants diagnosed by the Petersen
1991 criteria. Baseline demographic data
reported for 134 participants.
GENDER: 60 men; 74 women
AGE (y): MCI-MCI (stable) 61.9 ± 8.5; MCI-AD
73.9 ± 5.8; MCI-other dementia 71.1 ± 9.1
APOE ε4 carrier (%): MCI-MCI (stable) 19
(46); MCI-AD 53 (74); MCI-other dementia 5
(24)
MMSE: MCI-MCI 27.5 ± 2.0; MCI-AD 26.9 ±
1.4; MCI-other dementia 26.8.0 ± 1.2
Education: not reported
Sources of referral: not reported
Sources of recruitment: secondary care,
outpatients of memory disorder clinic,
University hospital, Malmo, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF p-tau/ABeta ratio
Cerebrospinal fluid was collected in polypropylene tubes, stored at -80 °C, and analysed after clinical
follow-up of the study was completed. No further details.
Threshold: determined at follow-up (page 102); a mixture model was used to establish accurate cutoff
value: used to identify optimal cut-offs: < 6.16
All tests
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia or
other forms of dementia
Reference standards: NINCDS-ADRDA and DSM-
III-R for Alzheimer's disease dementia; DSM-III-R
for vascular dementia; McKeith for Lewy bodies
dementia and Brun for frontotemporal dementia.
Clinicians conducting follow-up were blinded to
CSF biomarker results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: median 9.2 years
(range: 4.1 years to 11.8 years)
At baseline: 137 MCI participants
At follow-up:134 MCI: 72 MCI-AD; 21 MCI-
other dementias; 41 MCI-MCI (stable);
(page 99)
Number included in analysis: 134
Conversion to Alzheimer's disease
dementia:
sensitivity 88%; specificity 90% (page 102)
TP = 63; FP = 6; FN = 9; TN = 56
(calculated in RevMan5)
Loss to follow-up: 3 participants died before
completion of 4 years follow-up and were
excluded from the analyses because their
cognitive ability was uncertain.
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Eckerstrom 2010
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: retrospective analysis of the
longitudinal data
Retrospective recruitment of 42 participants with
MCI from the Gothenborg study: 21 MCI
converters and 21 MCI-stable participants. The
group of MCI converters comprised all MCI
converters who underwent a baseline MRI
investigation. The MCI-stable participants were
included consecutively to achieve matching
group size. No further details.
Twenty-six controls were also recruited. We only
included data on performance of the index test
to discriminate between participants with MCI
who converted to dementia and those who
remained stable.
Exclusion criteria: not reported.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
42 participants, diagnosed with the Global
Deterioration Scale (GDS) criteria (Reisberg
1998) at baseline. GDS criteria were not
prespecified diagnostic criteria for MCI.
Gender: 18 male; 24 female
Age: total sample: mean age 67.9 (range 51 to
78) years; MCI-MCI: 66.6 (range 56 to 78)
years; MCI-progressive: 69.3 (range 51 to 78)
years
APOEɛ4: not reported
MMSE: mean 27.8 (range 22 to 30); MCI-MCI:
28.3 (range 24 to 30); MCI-progressive: 27.2
(range 22 to 30)
Education: total sample: mean age 11.4 (range
6 to 19) years; MCI-MCI: 12.5 (range 8 to 19)
years; MCI-progressive: 10.4 (range 6 to 17.5)
years
Sources of referral: not reported
Sources of recruitment: University of
Gothenburg, Molndal, Sweden
Are there concerns that the included patients and setting do not match the
review question? Unclear
Index Test
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Index tests
CSF t-tau
CSF samples were collected by lumbar puncture (LP). Both baseline and follow-up lumbar punctures
were performed in the morning to exclude influences on the results from possible diurnal fluctuations in
biomarker levels. The samples
were collected in polypropylene tubes that were stored at –80 °C, without being thawed and refrozen,
pending biochemical analyses. All CSF analyses for a participant were performed on the same
occasion. CSF levels were determined using a sandwich enzyme-linked immunosorbent assay
constructed to measure tau.
Threshold: 500 ng/L, not prespecified. ROC curves were used to calculate the cutoff values based on
the maximum for the sum of sensitivity and specificity.
It was not reported whether the index test results were interpreted without knowledge of the results of
the reference standard.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to ADD
or FTD or subcortical VD or mixed AD/VD.
Reference standard: NINCDS-ADRDA criteria;
Lund and Manchester criteria; Erkinjunitti
criteria.
In addition, Global Deterioration Scale (GDS)
criteria (Reisberg 1998): score = 4 were used.
It was not reported whether the results of the
reference standard were interpreted without
knowledge of the results of the index test.
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 2 years
At baseline: 42 MCI participants
At follow-up: 21 MCI converters (13 MCI-AD; 4
MCI-VD; 2 MCI-FTD; 2 MCI-AD/VD); 21 MCI-
stable (MCI-MCI) (page 296)
21 MCI converters and 21 MCI non-converters
were selected from the Gothenborg study for the
retrospective analysis.
Number included in analysis: 42
Conversion to all types of dementia:
sensitivity 67%; specificity 95% (Table 3, page
298)
TP = 14; FP = 1; FN = 7; TN = 20 (Fig 1, page
297)
Insufficient data to create 2 X 2 table for
conversion from MCI to ADD.
Loss to follow-up: all retrospectively selected
participants were included in the analysis
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Fellgiebel 2007
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: prospective cohort study
Prospective recruitment of 16 participants
with amnestic mild cognitive impairment,
presenting at a memory clinic for diagnostic
evaluation. Sampling procedure not
described.
Exclusion criteria: participants with
metabolic disease that could affect cognitive
function; participants with other brain
diseases; participants with a diagnosis of
depression according to DSM-IV criteria.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
16 participants, diagnosed with the Petersen
1999 criteria at baseline. One participant of the
initial study group refused further participation
and was replaced by a consecutively recruited
comparable participant of the memory clinic to
preserve the statistical power for prospectively
planned follow-up analyses.
Gender: 9 male; 7 female
Age: total sample: mean age 68.6 ± 7.9 years;
MCI-MCI: 68.8 ± 10.0 years; MCI-progressive:
68.5 ± 5.9 years (4/8 MCI-AD: 69.5 ± 7.9 years)
APOEɛ4: not reported
MMSE: mean 25.7 ± 2.7; MCI-MCI: 27.3 ± 1.8;
MCI-progressive: 25.0 ± 2.1 (4/8 MCI-AD: 24.3
± 1.5)
Education: not reported
Sources of referral: not reported
Sources of recruitment: University Memory
Clinic, Germany
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF p-tau
Method of the index test administration described previously (Fellgiebel 2004). CSF was analysed with
two sandwich enzyme-linked immunosorbent assays: Tau protein phosphorylated at threonine 181 (p-
tau181) was determined using the Innogenetics INNOTEST Phospho-Tau(181) kit and total tau protein
(t-tau) was examined with the INNOTEST-hTau-Ag kit.
Threshold: Besides the previous published p-tau181 cutoff (Fellgiebel 2004), the cutoff value of 50
pg/mL was chosen as an optimal cutoff by means of Receiver Operating Characteristic (ROC)
analyses to separate participants with MCI from controls (measures in 75 participants, unpublished
data).
Not reported whether the index test results were interpreted without knowledge of the results of the
reference standard.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia.
Reference standard: progression to
Alzheimer's disease dementia was assumed if
CDR reached 1
Follow-up evaluation at variable time points
(not specified), comprising neurological and
psychiatric examination, CDR and MMSE.
Progressive cognitive decline was defined as
MMSE score reduction >/= 2 and a clinical
judgement of cognitive deterioration.
Clinicians conducting follow-up were blinded to
the CSF p-tau results.
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: total sample: 19.6 ± 9.0
months; MCI-MCI: 19.5 ± 9.3 months; MCI-
progressive: 17.6 ± 8.8 months (4/8 MCI-AD:
23.7 ± 2.0 months).
At baseline: 16 MCI: 12 CSF p-tau positive; 4
CSF p-tau negative.
At follow-up: 16 MCI: 12 CSF positive: 4 MCI-
AD (converters), 8 MCI-MCI (non-converters), 4
MCI-progressive (non-converters); 4 CSF p-tau
negative: 4 MCI-MCI (stable non-converters)
(page 170)
Number included in analysis: 16
Conversion to AD:
TP = 4; FP = 8; FN = 0; TN = 4
sensitivity: 100%; specificity: 33% (calculated in
RevMan5)
Loss to follow-up:1/16; however, that participant
was replaced by an additional, consecutively
recruited patient from the memory clinic
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Galluzzi 2010
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: retrospective analysis of the
longitudinal data.
Retrospective MCI group of 108 participants was
recruited consecutively in a previous prospective
study from the university memory clinic over 24
months.
Participants were excluded if they had a history
or presence of neurological signs of major stroke
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
90 participants, who had been diagnosed by the
Petersen 1999 criteria at baseline and had
follow-up assessment, were included in the
study. The remaining 18 participants were not
included in the study because they lacked
follow-up assessment due to refusal (n = 16) or
logistic problems (n = 2). CSF was obtained
only from 64 participants. Demographic data
were reported on 90 participants.
Gender: 37 men; 53 women
Age: mean 72.05 years; MCI-MCI: 70.09 ± 7.1;
MCI-AD: 72.2 ± 7.1; MCI-nAD: 25.5 ± 1.9
APOE ε4 carrier: 35; MCI-MCI: 19; MCI-AD: 14;
MCI-nAD: 2
MMSE: MCI-MCI: 26.3 ± 1.9; MCI-AD: 26.4 ±
1.6; MCI-other dementia: 73.0 ± 7.1
Sources of recruitment: secondary care,
outpatients from Translational Outpatient
Memory Clinic (TOMC), Brescia, Italy
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF t-tau
CSF was obtained by lumbar tap between L4 and L5 or L3 and L4 and processed, as detailed
elsewhere (Frisoni 2009). Levels of CSF proteins were determined by commercially available enzyme-
linked immunosorbent assay (Innogenetics, Belgium).
Threshold: > 450 pg/mL for subjects with an age range between 51 and 70 years determined; > 500
pg/mL for subjects with an age range between 71 and 93 years; threshold determined at baseline and
based on published criteria (page 2006).
Not reported whether the index test results were interpreted without knowledge of the results of the
reference standard.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia or other forms of dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of initial CSF analysis
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 24.0 ± 9.7 months
At follow-up: 39/90 participants converted to
dementia (Abstract)
Number included in analyses: 64
24 MCI with 'abnormal CSF t-tau level': 19 MCI
converters and 5 MCI-MCI; 40 MCI with 'normal
CSF t-tau level': 15 MCI converters and 25 MCI-MCI
(from Dr Galluzzi's email)
Conversion to all forms of dementia:
TP = 19; FP = 5; FN = 15; TN = 25
sensitivity = 56%; specificity = 83%
Loss to follow-up: 26 (24 participants refused the LP
procedure; 2 LPs were not performed due to
osteoarthrosis).
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes The trial investigators were contacted; they provided data tor the 2 X 2 table to be
completed for conversion to all forms of dementia. Normative data for CSF p-tau and
CSF t-tau/ABeta ratio were not available (email from Dr Galluzi on 9/12/13).
 
Hampel 2004
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: retrospective analysis of the
longitudinal data.
The MCI group was not a consecutive sample.
Retrospective recruitment of 52 participants with
MCI: 29 MCI converters and 23 MCI-stable
participants. In addition, 93 participants with
probable AD and 10 healthy, age-matched
controls were recruited from a hospital
rehabilitation department. We only included data
on performance of the index test to discriminate
between participants with MCI who converted to
dementia and those who remained stable.The
MCI group was not a consecutive sample and
was selected at follow-up.
No exclusion criteria were specified.
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
52 MCI participants diagnosed by the Petersen
1991 criteria at baseline.
Gender: 24 men; 28 women
Age: mean age 72.6 years (range 54 to 87)
APOE ε4 carrier: not reported
MMSE (all MCI): 28.9 ± 1 (range 26 to 30)
Sources of referral: not reported
Sources of recruitment: secondary care,
inpatients from Department of Rehabilitation,
Pitea, Sweden
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
CSF t-tau biomarker
CSF samples were taken by lumbar puncture, collected in polypropylene tubes, and stored at -80 ºC.
T-tau was measured in duplicate using a commercial ELISA (Innotest beta-amyloid 1-42, Innogenetics,
Belgium).
Threshold(s): ≥ 479 ng/L, established in the MCI-MCI vs MCI-AD at follow-up (page 707)
At follow-up: 14 with 'normal CSF t-tau level' and 38 with 'abnormal CSF t-tau level' (calculated in
RevMan5).
Unclear whether the index test results were interpreted without knowledge of the results of the
reference standard.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria; DSM-IV criteria. All MCI
participants were assessed with both
reference standards.
Unclear whether clinicians conducting
follow-up a were aware of initial CSF
analysis results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean 8.4 ± 5.1
months (range 2 to 24 months); follow-up
interval for converters was 9.6 ± 5.4, and
for non-converters 7.0 ± 4.3 months
At follow-up: 52 MCI: 29 MCI-AD; 23 MCI-
MCI (page 94)
Number included in analysis (N=52)
Conversion to Alzheimer's disease
dementia:
sensitivity 90%; specificity 48% (page 707);
disease positive: 29; disease negative: 23
TP = 26; FP = 12; FN = 3; TN = 11
(calculated in RevMan5)
Loss to follow-up: data for all 52 MCI
participants were reported
Was there an appropriate interval between index test and reference standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Hansson 2006
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A. Risk of Bias
Patient Sampling
Study design: nested case-control study with a
delayed verification design.
Prospective cohort of 180 participants with MCI,
who had sought medical advice for subjective
memory difficulties, was consecutively recruited
at a university hospital between July 1998 and
June 2001. 39 healthy controls were also
included, but appeared to have been used for
comparison purposes only and not included in
the ROC analysis.
Patients with other causes of cognitive
impairment, including brain tumour, subdural
haematoma, CNS infection, and current alcohol
abuse, were excluded.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
137 MCI participants, diagnosed by the
Petersen 1999 and Petersen 2004 criteria,
underwent successful lumbar puncture.
Baseline demographic data reported for 134
participants. Of the 43 participants with MCI
who did not undergo successful lumbar
puncture at baseline, 32 preferred not to go
through the procedure and in 11 the procedure
did not deliver usable CSF.
GENDER: 60 men; 73 women
AGE (median (range)): MCI-MCI (stable): 67
(50 to 86) years; MCI-AD 75 (59 to 85) years;
MCI-other dementia 76 (54 to 82) years
APOE ε4 carrier: MCI-MCI (stable): 28 (50%);
MCI-AD 43 (75%); MCI-other dementia 6
(29%)
MMSE: mean ± SD: MCI-MCI (stable) 27.3 ±
1.8; MCI-AD 26.8 ± 1.4; MCI-other dementia
27.0 ± 1.5
Education (higher): MCI-MCI (stable): 26
(46%); MCI-AD 18 (32%); MCI-other dementia
10 (48%)
Sources of referral: most participants (75%) by
family practitioners
Sources of recruitment: secondary care,
outpatients from memory disorder clinic,
University hospital, Malmo, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
CSF t-tau; CSF p-tau; CSF p-tau/ABeta ratio
CSF samples were obtained and stored in polypropylene tubes at –80ºC, and analysed after the
clinical follow-up of the study was completed.
T-tau, tau phosphorylated at threonine 181 (P-tau181), and ABeta42 concentrations were measured
with xMAP technology and the INNOBIA AkzBio3 kit (innogenetics), as previously described in detail
(Olssson 2005). The CSF concentrations of t-tau, p-tau181, and ABeta42 were highly correlated to the
concentrations obtained with conventional ELISA measurements. The best cutting values for the
different combinations of the CSF biomarkers were established in the whole control and MCI patient
material as those giving the highest Youden index (Youden 1950).
Threshold: > 350 pg/mL for CSF t-tau; ≥ 60 pg/mL for CSF p-tau; < 6.5 pg/mL for CSF p-tau/ABeta
It was not reported whether the index test results were interpreted without knowledge of the results of
the reference standard.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia or
other forms of dementia
Reference standards: NINCDS-ADRDA and DSM-
III-R for Alzheimer's disease dementia; NINDS-
AIREN and DSM-III-R for vascular dementia;
McKeith for Lewy bodies dementia and Brun for
frontotemporal dementia.
Clinicians making the diagnosis during follow-up
were unaware of all CSF analyses.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Duration of follow-up: total sample: median
5.2 years (range 4.0 to 6.8); MCI-AD:
median: 4.3 years (range 1.1 to 6.7); MCI-
other dementias: median 4.2 (1.5 to 6.3)
CSF t-tau
At baseline: 137 MCI participants with CSF
sample
At follow-up: 134:
38 MCI with baseline positive CSF t-tau: 29
MCI-AD; 4 MCI-other dementias; 5 MCI-
MCI;
96 MCI with baseline negative CSF t-tau: 28
MCI-AD; 17 MCI-other dementias; 51 MCI-
MCI
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Flow and timing
Number included in analysis: 134
1) Conversion to AD: TP = 29; FP = 9; FN =
28; TN = 68; sensitivity = 51%; specificity =
88% (calculated in Revman5)
2) Conversion to all dementias: TP = 33; FP
= 5; FN = 45; TN = 51; sensitivity = 42%;
specificity = 91% (calculated in Revman5)
CSF p-tau
At baseline: 137 MCI participants with CSF
sample
At follow-up: 134:
50 CSF p-tau positive: 39 MCI-AD; 2 MCI-
other dementias; 9 MCI-MCI;
84 CSF p-tau negative: 18 MCI-AD; 19 MCI-
other dementias; 47 MCI-MCI
Number included in analysis: 134
1) Conversion to AD: TP = 39; FP = 11; FN
= 18; TN = 66; sensitivity = 68%; specificity
= 86% (calculated in Revman5)
2) Conversion to all dementias: TP = 41; FP
= 9; FN = 37; TN = 47; sensitivity = 52%;
specificity = 84% (calculated in Revman5)
CSF p-tau/Aß ratio
At baseline: 137 MCI participants with CSF
sample
At follow-up: 134:
74 CSF p-tau/ABeta positive: 55 MCI-AD; 4
MCI-other dementias; 15 MCI-MCI;
60 CSF p-tau/ABeta negative: 2 MCI-AD; 17
MCI-other dementias; 41 MCI-MCI
Number included in analysis: 134
1) Conversion to AD: TP = 55; FP = 19; FN
= 2; TN = 58; sensitivity = 96%; specificity =
75% (calculated in Revman5)
2) Conversion to all dementias: TP = 59; FP
= 15; FN = 19; TN = 41; sensitivity = 76%;
specificity = 73% (calculated in Revman5)
Loss to follow-up: initially identified 180
consecutive participants with MCI; 43/180
not included in the study: 32 refused lumbar
puncture and 11 non-usable CSF samples;
3 participants died before 4 years of follow-
up (not included in the analysis)
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes The trial investigators contacted; they provided relevant data for creating 2 X 2 table
items (email on 29/11/13).
 
Herukka 2007
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A. Risk of Bias
Patient Sampling
Study design: nested case-control study with delay
verification design.
Participants examined in a university hospital neurological
department, or from an ongoing population-based study
were prospectively recruited if they agreed to a lumbar
puncture for research purposes and had a baseline
diagnosis of MCI; 79 participants met these criteria. 60
controls (who were referred to the neurological department
for different symptoms, or who were included in the
population-based study and had depression with normal
performance in neuropsychological tests) were also
included. We only included data on performance of the
index test to discriminate between participants with MCI
who converted to dementia and those who remained
stable.
No exclusion criteria were specified.
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
79 MCI participants diagnosed by the CDR =
0.5 criteria at baseline.
Gender: 33 men; 46 women
Age: 70.56 years; MCI-MCI: 69.46֨ ± 8.14;
MCI-progressive: 71.76 ± 6.71
APOE ε4 carrier: 41; MCI-MCI: 15/45
(33.3%); MCI-progressive: 26/33 (78.8%)
MMSE: MCI-MCI: 24.09 ± 2.49; MCI-
progressive: 23.91 ± 2.69
Sources of recruitment: secondary care,
inpatients from neurological department,
Kuopio University Hospital, Finland
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF t-tau; CSF p-tau
The CSF samples were collected by LP during the baseline visit. The samples were stored in
polypropylene tubes at -70 °C until analysis. The measurement of CSF t-tau and CSF P-tau were done
by using a commercial ELISA (Innogenetics, Belgium), blinded to the diagnoses.
Threshold: > 400 pg/mL for CSF t-tau; > 70 pg/L for CSF P-tau; thresholds determined at baseline
using previously published cutoff values from the ROC analysis (Herruka 2005)
Index test was conducted at baseline and interpreted blinded to the diagnoses of APOE genotype.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia
or other forms of dementia
Reference standard: NINCDS-ADRDA for
Alzheimer's disease dementia; DSM-IV-R criteria
for other dementias
Diagnosis of dementia was done independently
and blinded to CSF biomarker results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean 3.52 ± 1.95
years in MCI converters; mean 4.56 ± 3.09
years in MCI-stable
At follow-up:79 MCI: 33 MCI converters (27
MCI-AD; 1 MCI-SVD; 5 MCI-MD); 46 MCI-
MCI (page 509)
Number included in analyses = 79
Conversion from MCI to all dementias (Fig 1,
page 510):
1) CSF t-tau: TP = 26, FP = 17, FN = 7, TN =
29; sensitivity = 79%; specificity = 63%
(calculated in Revman5)
2) CSF P-tau:TP = 25, FP = 16, FN = 8, TN
= 30; sensitivity = 76%; specificity = 65%
(calculated in Revman5)
Loss to follow-up: CSF marker and follow-up
data appeared to have been available for all
participants.
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Kester 2011
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A. Risk of Bias
Patient Sampling
Study design: retrospective analysis of the
longitudinal data
153 participants with available CSF results and
APOE ε4 genotyping were diagnosed with MCI in
the memory clinic in the period between January
2001 and May 2008. 107 of those 153 participants
had follow-up data available and were
retrospectively recruited.
No exclusion criteria were reported.
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
107 MCI participants diagnosed by the
Petersen 1991 criteria at baseline. Baseline
demographic data reported for 100
participants, who were included in the analysis.
Gender: 59 men; 41 women. MCI-MCI: 38
men; 20 women; MCI-AD: 21 men; 21 women
Age: 67 ± 9 years MCI-MCI; 69 ± 7 years MCI-
AD
APOE ε4 carrier: 27/58 MCI-MCI; 30/42 MCI-
AD
MMSE: 27 ± 2 MCI-MCI; 26 ± 3 MCI-AD
Sources of referral: not reported
Sources of recruitment: secondary care,
outpatients from memory clinic, Amsterdam,
the Netherlands
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF t-tau biomarker
CSF was obtained by lumbar puncture between the L3/L4 and L4/L5 intervertebral space and
collected in10 mL polypropylene tubes. CSFsamples were processed within 2 hours (centrifuged at
1800 × g for 10 min at 4 °C and stored at -80 °C in polypropylene tubes until analysis). CSF t-tau was
measured using a commercial sandwich ELISA (Innotest).
Threshold(s): > 356 pg/mL abnormal level; determined at baseline and based on published data
(Schoonenboom 2005)
The index test results were interpreted without knowledge of the results of the reference standard.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia or other forms of dementia
Reference standard: NINCDS-ADRDA
criteria for Alzheimer's disease dementia;
Neary 1998 criteria; Roman 1993 criteria;
McKeth 2005 criteria
Not reported whether clinicians conducting
follow-up were aware of CSF biomarker
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: median 18 months (IQR 13 to
24); for MCI converters, the median was 17 months
(IQR 13 to 24); for MCI-stable the median was 18
months (IQR 12 to 25).
At follow-up: 107 MCI:
49 MCI converters (42 MCI-AD; 3 MCI-FTD, 2 MCI-
VD; 1 MCI-LBD; 1 MCI-dementia due to
hydrocephalus);
58 MCI-MCI (page 1373).
Number included in analyses: 100 MCI: 42 MCI-AD
and 58 MCI-MCI
36 with 'normal' CSF t-tau level and 64 with
'abnormal' CSF t-au level (Table 1, page 1374)
Conversion to AD:
TP = 35; FP = 29; FN = 7; TN = 29; sensitivity = 83%;
specificity = 50% (calculated in Revman5)
Missing data: 7 MCI participants who converted to
other forms of dementia were excluded from the
analysis.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Koivunen 2008
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A. Risk of Bias
Patient Sampling
Study design: nested case-control study with
a delayed verification design.
Prospective MCI group of 15 participants with
aMCI and 22 healthy controls were included.
We only included data on performance of the
index test to discriminate between participants
with MCI who converted to dementia and
those who remained stable. Sampling
procedure and exclusion criteria not
described.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
15 participants diagnosed by the Petersen
1999 criteria.
GENDER: 9 men; 6 women
AGE (y): mean age 71.1 ± 7.2
APOE ε4 carrier (%): not reported
MMSE: 25.1 (range 18 to 30)
Education: not reported
Sources of referral: not reported
Sources of recruitment: not reported. The
study was conducted in Finland.
Are there concerns that the included patients and setting do not match the
review question? Unclear
Index Test
Index tests
CSF t-tau; CSF p-tau; CSF p-tau/ABeta42
CSF sample was collected by lumbar puncture into polypropylene tubes and stored at –70 °C until
analysis. The CSF levels of ABeta42, total tau and p tau (181P) were measured by a commercial
ELISA (Innogenetics, Ghent, Belgium) according to the manufacturer’s protocol.
Threshold: CSF t-tau > 400 pg/mL; CSF p-tau < 70 pg/mL; CSF p-tau/ABeta42 < 6.5 pg/mL. The cut-
off values used were based on the own control material. No further information.
Index test was conducted before clinical follow-up. The ELISA analyses were done blinded to the
diagnosis.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's dementia
Reference standard: NINCS-ADRDA
criteria; DSM-IV criteria
Not reported whether clinicians conducting
follow-up were aware of CSF biomarkers'
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 2 years
At baseline: 15 MCI participants (10 CSF t-tau
abnormal tests; 9 CSF p-tau abnormal tests; 9
CSF p-tau/ABeta42 abnormal tests) (abstract)
At follow-up: 15 MCI: 6 MCI-AD (3 CSF t-tau
abnormal tests; 3 CSF p-tau abnormal tests; 4
CSF p-tau/ABeta42 abnormal tests); 9 MCI-
MCI (stable) (page 381)
Number included in analysis: 14
Conversion to Alzhemer's disease dementia:
CSF p-tau: TP = 2; FP = 7; FN = 3; TN = 2;
sensitivity = 40%; specificity = 22% (calculated
in Revman5)
CSF p-tau/ABeta42: TP = 4; FP = 6; FN = 1;
TN = 3; sensitivity = 80%; specificity = 33%
(calculated in Revman5)
Loss to follow-up: CCF p-tau result was not
available for one MCI-AD participant
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes The trial investigators were contacted and asked for the relevant data for CSF t-tau
(email on 30/12/13). No further information was available at the time this review was
prepared.
 
Monge-Argiles 2011
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A. Risk of Bias
Patient Sampling
Study design: nested case-control study with a
delayed verification design
Prospective MCI group of 37 MCI participants,
attending the cognitive deterioration outpatients
clinic of a general hospital, and 24 control
subjects without subjective memory loss or
known cognitive deterioration were recruited.
No further details. We only included data on
performance of the index test to discriminate
between participants with MCI who converted to
dementia and those who remained stable.
Participants with dementia or other
neurological, psychiatric or medical disease
which could provoke cognitive deterioration,
anticoagulant therapy, failure to obtain informed
consent, or a Yesavage depression scale score
> 5 were excluded.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
37 participants diagnosed by the Petersen
2006 criteria at baseline;
Gender: 13 men; 24 women; MCI-MCI: 11
men, 15 women; MCI-AD: 2 men, 9 women
Age: mean 73.43 ± 6.63 years
APOEε4 carrier: not reported
MMSE: mean 25 ± 2.4; MCI-AD: mean 23 ±
1.2
Sources of recruitment: secondary care,
outpatients from General Hospital, Spain
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSFt-tau; CSF p-tau; CSF t-tau/ABeta ratio; CSF p-tau/ABeta ratio
The LP was performed by a hospital neurologist with a 20 X 3.5 gauge needle. CSF was collected in
standard tubes and centrifuged if little sanguinolent, before being frozen. CSF samples with obvious
blood were discarded. CSF biomarkers were analysed using xMAP Luminex technology and INNO-
BIA Alzbio3 reagents (Innogenetics, Belgium).
Threshold(s): 77.5 pg/mL for CSF t-tau; 54.5 for CSF P-tau; 0.18 for CSF t-tau/ABeta ratio; 0.17 for
CSF P-tau/ABeta ratio (Table 6, page 990); thresholds determined at follow-up: ROC curve analysis
was performed to determine the best cutoff values for measurement of variables. The best cutoff value
was defined taking into account the highest sensitivity.
Index test was conducted before clinical follow-up and all samples were blindly analysed with respect
to the clinical data.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
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Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion to Alzheimer's
disease dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 6 months
At baseline: 37 MCI
At follow-up: 11 MCI-AD; 26 MCI-MCI (Table
1, p 989)
Number included in analyses=37
Conversion to Alzheimer's disease dementia:
1) CSF t-au: sensitivity 72.7%; specificity 70%
(Table 6, page 990)
TP = 8, FP = 8, FN = 3, TN = 18 (calculated in
RevMan5)
2) CSF p-tau: sensitivity 82%; specificity 58%
(Table 6, page 990)
TP = 9, FP = 11, FN = 2, TN = 15 (calculated
in RevMan5)
3) CSF t-tau/ABeta ratio: sensitivity 91%;
specificity 50% (Table 6, page 990)
TP = 10, FP = 13, FN = 1, TN = 13 (calculated
in RevMan5)
4) CSF p-tau/ABeta ratio: sensitivity 82%;
specificity 66% (Table 6, page 990)
TP = 9, FP = 9, FN = 2, TN = 17 (calculated in
RevMan5)
Loss to follow-up: CSF marker and follow-up
data appeared to have been available for all
participants.
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Palmqvist 2012
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A. Risk of Bias
Patient Sampling
Study design: prospective cohort study
133 participants were ”randomly recruited”
among those fulfilling the MCI criteria who were
referred to the memory clinic between 2000 and
2006. There were several people during this
period who were not included due to
administrative causes (information from the
author).
Exclusion criteria were not described.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
133 MCI participants, diagnosed with the
Petersen 2004 criteria, were recruited from the
Memory Clinic of University Hospital in Malmo,
Sweden. At the initial visit, all participants were
assessed by physicians experienced in dementia
disorders, and underwent thorough physical,
psychiatric and neurological examinations, as
well as an interview that focused on their
cognitive symptoms and ADL function.
Gender: MCI-MCI: 34 women, 28 men; MCI-AD:
36 women, 16 men; MCI-other dementias: 8
women, 11 men
Age (y): MCI-MCI: mean 69.8 (range 55 to 85);
MCI-AD: 75.3 (range 55 to 87); MCI-other
dementias: 71.2 (59 to 83)
APOEε4 carrier (%): MCI-MCI: 28 (45); MCI-AD:
39 (76); MCI-other dementias: 12 (63)
MMSE: MCI-MCI: mean 28.1 ± 1.2; MCI-AD:
mean 26.1 ± 1.5; MCI-other dementias: mean
27.1 ± 2.0
Education: not reported
Sources of referral: most participants were
referred from primary care units, but some
referrals came from other clinics at the hospital.
Sources of recruitment: memory clinic, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF t-tau; CSF p-tau; CSF t-tau/ABeta ratio
CSF was collected at baseline in polypropylene tubes and gently mixed to avoid gradient effects. All
samples were centrifuged within 30 minutes at +4 uC at 2000 g for 10 min to remove cells and debris.
Samples were stored in aliquots at -80 oC pending biochemical analysis. The procedure used and the
analysis of the CSF followed the Alzheimer’s Association Flow Chart for lumbar puncture (Blennow
2010) . The Luminex xMAP technology was used to determine the levels of tau, ABeta42 and p-tau
(Ollson 2005). In addition to tau, ABeta42 and p-tau, the ratio of ABeta42/tau was tested as a separate
variable in the logistic regression models since it previously had shown high predictive accuracy in this
cohort (Hertze 2010) . Lumbar puncture was only conducted at the initial visit.
Threshold: CSF t-tau: > 87 pg/mL; CSF p-tau: > 39 pg/mL. The cut-offs were optimised (page e38639)
Not reported whether the index test results were interpreted without knowledge of the results of the
reference standard.
All tests
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia or other
forms of dementia
Reference standards: NINCDS-ADRDA for AD; NINDS-
AIREN/Erkinjuntti for VaD; McKeith for DLB
Clinicians conducting follow-up were not aware of CSF
biomarker results (page e38639)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean 5.9 years
(range: 3.2 to 8.8)
At baseline: 133 MCI participants
At follow-up: 62 MCI-MCI; 52 MCI-AD; 19
MCI-other forms of dementias (Table, 2;
page e38639)
Number included in analysis: 133
Conversion to Alzheimer's disease
dementia:
1) CSF t-tau: sensitivity = 80%; specificity =
72% (Table, 2; page e38639)
TP = 42; FP = 23; FN = 10; TN = 58
(calculated in RevMan5)
2) CSF p-tau: sensitivity = 67%; specificity
= 86% (Table, 2; page e38639)
TP = 35; FP = 11; FN = 17; TN = 70
(calculated in RevMan5)
Note: the accuracy of the CSF t-tau/ABeta
ratio not reported
Loss to follow-up: none
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
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Notes The author contacted regarding the sample procedure (Dr Palmqvist email on
28/2/14). Data for CSF t-tau/ABeta ratio not available.
 
Parnetti 2012
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: nested case-control study with a
delayed verification design
454 participants were consecutively referred to
the memory clinic for a first diagnostic
assessment of cognitive disturbances during the
period 2005 to 2007. A prospective MCI group
of 90 participants were recruited. 28 participants
with AD were also enrolled in the study. We only
included data on performance of the index test
to discriminate between participants with MCI
who converted to dementia and those who
remained stable.
No exclusion criteria were specified.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
90 participants diagnosed by the Petersen
1999 criteria at baseline and had follow-up
assessment at least once a year during four
years.
Gender: total: 66 men; 34 women
Age (y): MCI-MCI: mean 66.35 ± 8.22; MCI-
AD: mean 67.23 ± 9.04
APOE ε4 carrier: not reported
MMSE: MCI-MCI: 27.28 ± 1.47; MCI-AD:
26.66 ± 1.58
Sources of referral: not reported
Sources of recruitment: memory clinic, Clinica
Neurologica, Universita degli Studi di Perugia,
Italy
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF p-tau/ABeta1-42 ratio; CSF t-tau; CSF p-tau; CSF t-tau/ABeta1-42 ratio
Data available only for the CSF p-tau/ABeta1-42 ratio. Authors contacted.
Lumbar puncture was performed after an overnight fasting. CSF (10 mL) was collected in sterile
polypropylene tubes, centrifuged for 10 min at 3000 × g and divided in 0.5 mL aliquots which were
immediately frozen at−80 oC. CSF A1-40 was measured using a commercially available ELISA
(IBL International, Japan) following instruction from the manufacturer. CSF ABeta1-42, total tau,
and p-tau were measured with ELISA method (Innotest ABeta1-42, hTAU-Ag, p-tau 181 Ag,
Innogenetics NV, Gent, Belgium) (Andreasen 1999; Blennow 1995)
Threshold: 1074.0 for CSF p-tau/ABeta1-42 ratio. Cutoff values were calculated using sensitivity and
specificity values that maximized Youden’s index (Youden 1950).
Not reported whether the index test results were interpreted without knowledge of the results of the
reference standard.
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All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease.
Reference standard: not specified. MCI
participants were clinically evaluated at
least once a year during 4-year follow-up
period (p 230). However, it was reported
that the NINCDS-ADRDA criteria were
used at baseline to identify AD diagnostic
group.
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up (y): mean 3.40 ± 1.01
(maximum 4 years)
At baseline: 90 MCI participants
At follow-up: 90 MCI: 32 MCI-AD; 58 MCI-MCI
(stable); (page 230)
Number included in analysis: 90
Conversion to Alzheimer's disease dementia:
CSF p-tau/ABeta1-42 ratio: sensitivity 81%;
specificity 95% (page 233)
TP = 26; FP = 3; FN = 6; TN = 55 (calculated in
RevMan5)
Loss to follow-up: none
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Unclear
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes Trial investigators contacted. Missing data requested for CSF t-tau, CSF p tau and
CSF t-tau/ABeta1-42 ratio biomarkers. No further information was available at the time
this review was prepared.
 
Visser 2009
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: nested case-control study with a
delayed verification design
Prospective group of participants with SCI,
naMCI and aMCI were recruited from 20 memory
clinics across Europe, between January 2003
and June 2005, into the prospective DESCRIPA
cohort study. Neurologically healthy controls
were also recruited. Sampling procedure for a
MCI cohort not described. We only included data
on performance of the index test to discriminate
between participants with MCI who converted to
dementia and those who remained stable.
Exclusion criteria were a diagnosis of dementia
or any somatic, psychiatric, or neurological
disorder that might have caused the cognitive
impairment.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
168/193 participants from the DESCRIPA
cohort with an available CSF baseline
sample were included in the study. The data
overlapped with the data from the Vos 2013
paper. However, we considered different
CSF biomarkers in those two studies.
Gender: 88 men; 80 women
Age (years): 70.0 ± 7.7 naMCI; 70.0 ± 7.7
aMCI; 66.0 ± 7.9 SCI
MMSE: 27.6 ± 2.2 naMCI; 25.9 ± 2.8 aMCI;
28.8 ± 1.2 SCI
Sources of recruitment: European
multicentre memory clinics
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF p-tau; CSF p-tau/ABeta ratio
CSF was collected by lumbar puncture, centrifuged, and stored at –80 °C in polypropylene tubes,
except where specified. The investigators measured CSF biomarkers with single-parameter ELISA kits
(Innotest β-amyloid [1–42]; Innotest hTAU-Ag; Innotest Phospho-tau [¹⁸¹P]; Innogenetics, Ghent,
Belgium). Analyses were done at one laboratory (Clinical Neurochemistry Laboratory, Sahlgrenska
University Hospital, Sweden) by operators who were blinded to all clinical information.
Threshold (positive test): CSF p-tau: i) ≥ 51 pg/mL (used in clinic) and ii) ≥ 85 pg/mL (> 90th percentile
controls after correction for age); CSF p-tau/ABeta ratio: ˂ 9.92 (< 10th percentile of reference group
after correction for age)
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria; DSM-IV criteria
Diagnosis of dementia was conducted
blinded to results of CSF biomarker
analysis (page 621).
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: range 1 to 3 years
193 participants in the DESCRIPA cohort had CSF
samples collected. Twenty-five participants were not
included in the study: 6 had no neuropsychological test
done at baseline; 11 had CSF collected at follow-up but
not at baseline; 8 had insufficient CSF left for central
analysis.
At baseline: N = 168 (MCI = 108 and SCI = 60)
Number included in analysis: N = 158
Conversion to AD:
1.a) CSF p-tau threshold: ≥ 51 pg/mL (used in clinic).
TP = 31; FP = 77; FN = 4; TN = 46 (unpublished data
obtained from the author); sensitivity = 88%; specificity =
37% (calculated in Revman5)
1.b) CSF p-tau threshold: ≥ 85 pg/mL (> 90th percentile
controls after correction for age)
TP = 20; FP = 25; FN = 15; TN = 98 (unpublished data
obtained from the author); sensitivity = 58%; specificity =
80% (calculated in Revman5)
2) CSF p-tau/ABeta ratio threshold: ˂ 9.92 (< 10th
percentile of controls after correction for age)
TP = 28; FP = 49; FN = 7; TN = 74 (unpublished data
obtained from the author); sensitivity = 80%; specificity =
60% (calculated in Revman5)
Loss to follow-up: 10 (CSF follow-up data were not
available; the reason not given)
Was there an appropriate interval between index test and
reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes The trial investigators contacted; they provided requested data tor the 2 x 2 table to be
completed; email from Dr Visser on 14/4/14
 
Vos 2013
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: prospective cohort study
399 participants with aMCI and 226
participants with naMCI from the DESCRIPA
cohort and Alzheimer Centre of the VU
University medical centre (VUmc).
DESCRIPA is a European multicentre study
performed in a memory clinic setting and
enrolled subjects between 2003 and 2005.
For this study, 431 eligible subjects were
selected from 16 participating centres in
which CSF was collected, MRI was
performed, or APOE genotype was
determined. The VUmc centre was one of
the DESCRIPA centres and contributed an
additional sample of 194 subjects that were
seen outside the DESCRIPA inclusion period
with data on CSF, MRI, or APOE measures.
No differences in biomarkers were found
between subjects from the VUmc centre in
the DESCRIPA study and those from the
additional VUmc sample. The sampling
procedure was not described.
Exclusion criteria were diagnosis of
dementia at baseline or any other somatic,
psychiatric or neurological disorder that
might have caused the cognitive impairment.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
231/635 had available CSF data and were
included in the review. 214/235 MCI
participants, diagnosed by Petersen 2004
criteria at baseline, had a least one follow-up
assessment. Baseline demographic data
reported on all 625 participants. There was
some data overlap with the data from the
Visser 2009 paper. However, we considered
different CSF biomarkers from those two
studies.
Gender: 270 men; 335 women
Age: 70.7 ± 7.6 years naMCI; 70.7 ± 7.8 aMCI
MMSE: 27.5 ± 2.1 naMCI; 26.5 ± 2.5 aMCI
Sources of recruitment: European multicentre
memory clinics
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
CSF t-tau; CSF t-tau/ABeta ratio
CSF was collected by lumbar puncture, centrifuged, and stored at -80 °C in polypropylene tubes.
Three samples were thawed twice but analyses without these samples revealed similar results. CSF
ABeta1-42 and total tau (t-tau) were measured by experienced technicians using commercially
available sandwich ELISAs (Innotest ABeta-amyloid 1-42; Innotest hTAU-Ag; Innogenetics, Ghent,
Belgium), specially constructed to measure ABeta-amyloid 1-42 and t-tau, at the lab in Gothenburg for
the DESCRIPA cohort and in Amsterdam for the additional subjects of the VUmc cohort. We corrected
for inter-laboratory ELISA differences by analysing 33 samples at both labs and we adjusted VUmc
values to those of DESCRIPA using the following formula: Gothenborg = (SD Gothenborg/SD VUmc) *
VUmc + average Gothenborg – ((SD Gothenborg/SD VUmc) * average VUmc).
Threshold (positive test): CSF t-tau: > 450 pg/mL for age less than 70 years; > 500 pg/mL for age
older than 70 years;
CSF t-tau/ABeta ratio: ABeta1–42/(240 1 [1.18 3 t-tau]) ˂ 1.0.
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria; DSM-IV criteria
Diagnosis of dementia was conducted
blinded to results of CSF biomarker
analysis (page 8).
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: mean 2.5 years
(maximum duration 5 years); follow-up was
performed annually
At baseline: 231 MCI
At follow-up: 214 MCI: 91 MCI-AD; 123 MCI-
MCI
Number included in analysis: 214 
Conversion to Alzheimer's disease dementia
(data obtained from Dr Vos):
1) CSF t-tau
TP = 65; FP = 28; FN = 26; TN = 95;
sensitivity = 71%; specificity = 77%
2) CSF t-tau/ABeta ratio
TP = 87; FP = 60; FN = 4; TN = 63;
sensitivity = 96%; specificity = 51%
Loss to follow-up: 17 participants did not
have a follow-up assessment (some refused
to participate or were untraceable or died
before follow-up)
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes The trial investigators contacted; they provided requested data tor the 2 x 2 table to be
completed; email from Dr Vos on 14/4/14
 
Footnotes
AD: Alzhemer's disease; ADD: Alzheimer's disease dementia; ADL: activities of daily living; aMCI: amnestic mild cognitive impairment; APOEε4:
Apolipoprotein E epsilon-4; CDR: clinical dementia rating; CNS: central nervous system; CSF: cerebrospinal fluid; DLB: Dementia with Lewy Bodies;
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders-III-Revised; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders-IV-Revised;
ELISA: enzyme-linked immunoabsorbent assay; FTD: fronto-temporal dementia; GDS: Global Deterioration Scale; IQR: interquartile range; LP: lumbar
puncture; MCI: mild cognitive impairment; MMSE: mini-mental state examination; nAD: non-Alzheimer's disease; naMCI: non-amnestic mild cognitive
impairment; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related
Disorders Association; NINDS-AIREN: National Institute of Neurological Disorders and Stroke and Association and Internationale pour la Recherché et
l'Enseignement en Neurosciences; ROC: receiver operating characteristics; SCI: subjective cognitive impairment; VaD: vascular dementia
Notes: Mattson 2009 is important and one of the single most defining studies in the field. However, we were not able to
include it in our review because there was an overlap between participants in the Mattsson 2009 paper and participants
assessed in the seven studies included in our review: Buchhave 2012; Eckerstrom 2010; Hansson 2006; Herukka 2007;
Kester 2011; Palmqvist 2012; Visser 2009; therefore, we identified this paper as a ‘multiple publication’ and added it to those
seven studies
Characteristics of excluded studies 
Desikan 2011
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: target condition was not
conversion from MCI to dementia. The focus of the study was to asses relationship
between neurodegeneration, amyloid Aß and CSF t-tau in MCI and healthy elderly
controls. ADNI participants.
 
Forlenza 2010
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used. The
objective of the study was to examine CSF biomarker levels between MCI-AD
converters and MCI-MCI stable participants.
 
Holland 2012
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Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used.
Annual changes in CSF biomarker levels were considered.The focus of the study was
to asses the effects of age on rates of clinical decline.
 
Ivanoiu 2005
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used. The
objective of the study was to examine prediction of progression to Alzheimer's disease
and correlation with neuropsychological examination.
 
Jack 2011
Reason for exclusion ADNI study. Not having data for constructing a 2 X 2 table. Study design: threshold not
used. Target condition was not conversion from MCI to dementia. The objective of the
study was to empirically assess the concept that Alzheimer's disease biomarkers
significantly depart from normality in a temporarily ordered manner.
 
Jagust 2009
Reason for exclusion ADNI study. Not having data for constructing a 2 X 2 table. Study design: threshold not
used. Target condition was not conversion from MCI to dementia. The objective of the
study was to assess relationship between biomarkers in ageing and dementia.
 
Lanari 2009
Reason for exclusion Insufficient data to complete 2 X 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Landau 2010
Reason for exclusion ADNI study. Insufficient data to complete 2 X 2 tables. Additional data were requested
from the trial investigators but no further information was available at the time this
review was prepared.
 
Maruyama 2004
Reason for exclusion Insufficient data to complete 2 X 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Maruyama 2004b
Reason for exclusion Insufficient data to complete 2 X 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Mattsson 2012
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: retrospective analysis.
The objective of the study was to evaluate changes in biomarker levels between MCI-
AD converters and MCI-MCI stable participants over time.
Participants: 15 MCI-AD and 15 MCI-MCI participants selected from a 4-year follow-up
study.
 
Nordlund 2010
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Reason for exclusion Insufficient data to complete 2 X 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Okamura 2002
Reason for exclusion Insufficient data to complete 2 X 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Okonkwo 2011
Reason for exclusion ADNI study. Not having data for constructing a 2 X 2 table. Index test: combined CSF
biomarkers. The relevant data for each individual CSF biomarker were not available.
 
Pereira 2010
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used. The
objective of the study was to examine the pattern of functional impairment in the
continuum MCI-AD.
 
Perneczky 2011
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used. The
accuracy of CSF t-tau not evaluated. CSF t-tau levels measured in different diagnostic
groups.
 
Riemenschneider 2002
Reason for exclusion Insufficient data to complete 2 X 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Samtani 2012
Reason for exclusion ADNI study. Not having data for constructing a 2 X 2 table. Study design: threshold not
used. Target condition was not conversion from MCI to dementia. The objective of the
study was to develop a semi-mechanistic disease progression model for MCI
participants.
 
Schneider 2010
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: target condition was not
conversion from MCI to dementia. The aim of the study was to test the
recommendation of including MCI participants with low CSFamyloid ABeta and high
CSF t-tau/ABeta ratio biomarkers in clinical trials, in order to improve efficiency of the
RCT.
 
Shaw 2009
Reason for exclusion ADNI study. Not having data for constructing a 2 X 2 table. The aim of the study was
to develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease in
ADNI participants.
 
Sluimer 2010
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Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used.
Annual changes in CSF biomarker levels were considered. The focus of the study was
to assess the association between CSF biomarker levels and MRI-based whole brain
atrophy rate in MCI and AD.
 
Snider 2009
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used. The
aim of the study was to determine whether baseline CSF biomarker’s levels predict a
rate of cognitive change, measured by CDR-SB (Clinical Dementia Rating Sum of
Boxes score) in participants with very mild DAT (CDR = 0.5 and Berg 1998 standard
criteria)
 
Van Harten 2012
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: target condition was
clinical progression, not conversion from MCI (SMC) to Alzheimer's disease dementia,
in participants with cognitive complaints. According to our inclusion criteria, we
considered participants with ‘subjective memory complaints’ (Matthew 2008).
 
Verwey 2008
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used.
Target condition not conversion from MCI to dementia. The focus of the study was to
evaluate changes in CSF levels of tau and p-tau over time.
 
Walhovd 2010
Reason for exclusion ADNI study. Not having data for constructing a 2 X 2 table. Study design: threshold not
used. Target condition was not conversion from MCI to Alzheimer's disease dementia.
The aim of the study was to assess an overall classification accuracy of biomarkers for
diagnostic groups (for instance, controls vs AD), or to assess predictive accuracy of
clinical change in MCI.
 
Wang 2012
Reason for exclusion Not having data for constructing a 2 X 2 table. Study design: threshold not used.
Target condition was not conversion from MCI to Alzheimer's disease dementia. The
aim of the study was to determine whether CSF proteins were associated with
hippocampal degeneration in participants with clinically diagnosed early AD.
 
Westman 2012
Reason for exclusion ADNI study. Insufficient data to complete 2 X 2 tables. Additional data were requested
from the trial investigators. The accuracy of the combination of the three CSF
biomarkers (ABeta42, t-tau and p-tau) was assessed. The author could not provide us
with the relevant data for each individual CSF biomarker.
 
Yang 2012
Reason for exclusion ADNI study. Not having data for constructing a 2 X 2 table. The accuracy of the
combined CSF biomarkers, as well as the accuracy of the combination of those CSF
and structural biomarkers were assessed. The relevant data for each individual CSF
biomarker were not reported.
 
Footnotes
AD: Alzheimer's disease; ADNI: Alzheimer Disease Neuroimaging Initiative; CDR-SB: Clinical Dementia Rating Sum of Boxes score; DAT: dementia
Alzheimer's type; MCI: mild cognitive impairment; SMC: subjective memory complaints 
Characteristics of studies awaiting classification 
Balasa 2014
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Patient Sampling Study design: nested case-control study with a delayed verification design.
120 participants with early onset of cognitive impairment (51 MCI; 42 AD; 10 FTD; 3
posterior cortical atrophy; 14 primary progressive aphasia), who were referred to
outpatient clinic at the Hospital Clinic Barcelona, were recruited prospectively between
January 2009 and March 2013. Thirty-seven control subjects were also recruited. We
only included data on performance of the index test to discriminate between
participants with MCI who converted to dementia and those who remained stable.
Exclusion criteria: not reported.
 
Patient characteristics and setting 51 participants with MCI (25 amnestic; 20 amnestic multi-domain; 6 non-amnestic)
diagnosed by Petersen 2004 criteria will be included in an updated review.
GENDER: 28 men; 23 women
AGE (y): 57.9 ± 6 (range = 37 to 66)
APOE 4 carrier (%): 37.5
MMSE (SD): 25.6 ± 6
Education: not reported
Sources of referral: not reported
Sources of recruitment: Alzheimer’s Disease and Other Cognitive Disorders Unit
outpatient clinic at the Hospital Clinic Barcelona, Italy
 
Index tests CSF ABeta42/p-tau ratio
All participants underwent lumbar puncture during the morning. The samples were
centrifuged and stored in polypropylene tubes at −80 ºC within 2 hours. Levels of
ABeta42, t-tau, and p-tau were measured by experienced laboratory personnel using
commercial sandwich ELISA kits (Innogenetics, Gent, Belgium).
Threshold: prespecified; the ABeta42/p-tau ratio was used in order to classify all the
subjects as CSF positive (ratio ABeta42/p-tau < 6.43) or negative (ratio ABeta42/p-tau
≥ 6.43).
 
Target condition and reference
standard(s)
Target condition: conversion from MCI to Alzheimer’s disease dementia
Reference standard: NIA-AA workgroup recommendations
 
Flow and timing Duration of follow-up: 41 months for MCI-AD; 30 months for MCI-MCI
At baseline: 51 MCI: 25 MCI with positive CSF biomarker; 26 MCI with negative CSF
biomarker (Figure 1, p 924)
At follow-up: 25 MCI with positive CSF biomarker: 24 MCI-AD and 1 MCI
nonconverters; 26 MCI with negative CSF biomarker: 26 MCI nonconverters; 0 MCI
converters; D+ (disease positive) = 24; D- (disease negative) = 27
Number to be included in analysis: (N = 51)
Conversion to ADD:
TP = 24; FP = 1; FN = 0; TN = 26 (Fig 1, p 924)
sensitivity = 100%; specificity = 96% (calculated in RevMan5)
 
Comparative  
Notes Authors need to be contacted in order to confirm that our calculation based on the
information from Figure 1, p 924 is correct.
Participants: MCI participants with early onset of cognitive impairment (age < 65
years). This needs to be taken into consideration if the study is going to be included in
an updated review.
 
Eckerstrom 2015
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Patient Sampling Study design: retrospective analysis of the longitudinal data; this is a sub-study of the
Gothenborg MCI study.
We included data on performance of the index test to discriminate between
participants with MCI who converted to dementia and those who remained stable.
Exclusion criteria: age > 79 or < 40, Mini Mental State Examination (MMSE) score <
19, acute/unstable somatic disease, severe psychiatric disorder, substance abuse or
confusion caused by drugs.
 
Patient characteristics and setting 73 participants diagnosed with the Global Deterioration Scale (GDS) criteria (Reisberg
1998) at baseline: 34 MCI converters (18 MCI-AD; 16 MCI-non-AD) and 39 MCI-
stable.
GENDER: 14 men and 25 women MCI-stable; 13 men and 21 women MCI converters
AGE (y): 64.4 ± 7.0 MCI-stable; 66.9 ± 6.9 MCI converters
APOE 4 carrier (%): 16/39 (41%) MCI-stable; 24/34 (71%) MCI converters
MMSE: 28.6 ± 1.4 MCI-stable; 27.6 ± 2.0 MCI converters
Education: 12.4 ± 3.8 MCI-stable; 11.3 ± 4.0 MCI converters
Sources of referral: not reported
Sources of recruitment: University of Gothenburg, Molndal, Sweden
 
Index tests CSF p-tau; CSF t-tau/ABeta42 ratio
CSF samples were collected by lumbar puncture, which was performed in the morning
to exclude influence on the results from possible diurnal fluctuations in biomarker
levels. CSF samples were collected in a polypropylene tube, and immediately
transported to the local laboratory for centrifugation. They were stored at −80 ºC,
without being thawed and refrozen, pending biochemical analyses. CSF T-tau, P-
tau181, and ABeta42 levels were determined using sandwich enzyme-linked
immunosorbent assays (INNOTEST® hTau Ag, INNOTEST® PHOSPHO-TAU(181P),
and INNOTEST® !-AMYLOID(1-42), respectively) from Innogenetics.
Threshold: CSF p-tau: 73; CSF t-tau/ABeta42 ratio: 0.85 (p 207); not prespecified.
ROC curves were used to calculate the cutoff values based on the maximum for the
sum of sensitivity and specificity
 
Target condition and reference
standard(s)
Target condition: conversion from MCI to Alzheimer’s disease dementia or ‘all
dementia’
Reference standard: NINCDS-ADRDA criteria
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Flow and timing Duration of follow-up: 43.1 ± 23 months MCI-stable; 33.7 ± 24 months MCI converters
At baseline: 73 MCI participants
At follow-up: 34 MCI converters (18 MCI-AD; 16 MCI-non-AD) and 39 MCI-stable.
Note: One patient (MCI-stable) declined LP. Additionally, analysis of CSF p-tau could
not be performed on 9 patients (7 MCI converters, 2 MCI-stable) due to lack of CSF.
Table 2, p 208: CSF p-tau reported in 63/73 participants; number of MCI participants
with the CSF t-tau/ABeta
Beta42 ratio value not reported
Number included in analysis: (N = 63)
CSF p-tau: at follow-up, 27 MCI converters; 36 MCI-stable; D+ (disease positive) = 27;
D- (disease negative) = 36
Conversion to ‘all dementia’:
sensitivity = 44%; specificity = 92% (Table 3, p 209)
TP = 12; FP = 3; FN = 15; TN = 33 (calculated in Revman5)
Conversion to ADD:
sensitivity = 75%; specificity = 92% (Table 4, p 209)
Insufficient data to create 2 X 2 tables. It was not reported in which 7MCI (?MCI-AD;
?MCI-non-AD) CSF p-tau was not performed.
CSF t-tau/ABeta42
Note: The accuracy data of CSF t-tau/ABeta42 ratio biomarker not reported
 
Comparative  
Notes Authors need to be contacted in order to obtain missing data. Check with the authors
whether the sensitivity and specificity values given in Table 3 and Table 4 relate to a
threshold given for CSF p-tau.
 
Ewers 2012
Patient Sampling Study design: nested case-control study with a delayed verification design
Subjects with a complete data set of CSF, MRI and neuropsychological tests were
drawn from the ADNI data set including 130 participants with amnestic MCI, 81
participants with AD, and 101 elderly healthy controls. We only included data on
performance of the index test to discriminate between participants with MCI who
converted to dementia and those who remained stable.
Exclusion criteria: not reported.
 
Patient characteristics and setting 130 participants with amnestic MCI will be included in an updated review. Diagnostic
criteria for amnestic MCI: subjective memory impairment and objective memory
impairment identical to that for AD; a CDR of 0.5 including the memory box score of
0.5 or greater, and a MMSE score between 24 and 30; unimpaired general cognitive
ability; functional performance such that participants with MCI did not meet criteria for
dementia.
GENDER: 44 men and 28 women MCI-stable; 39 men and 19 women MCI-AD
AGE (y): 73.4 ± 7.4 MCI-stable; 74.6 ± 7.3 MCI-AD
APOE 4 carrier (%): 46 MCI-stable; 65.5 MCI-AD
MMSE: 27.4 ± 1.6 MCI-stable; 26.9 ± 1.8
Education: not reported
Sources of referral: not reported
Sources of recruitment: ADNI participants
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Index tests CSF t-tau; CSF p-tau
All CSF samples collected at the different centres were shipped on dry ice to the Penn
ADNI Biomarker Core Laboratory at the University of Pennsylvania, Philadelphia for
storage at -80 °C until further analysis at the laboratory. The concentration of CSF
biomarkers was measured in the baseline CSF samples using Innogenetics reagents
(research use only AlzBio3 immunoassay kits, Ghent, Belgium) and the multiplex
xMAP Luminex platform (Lumnix Corporation, Austin, TX) at the Penn ADNI Biomarker
Core Laboratory
Threshold: not reported
 
Target condition and reference
standard(s)
Target condition: conversion from MCI to Alzheimer’s disease dementia
Reference standard: NINCDS-ADRDA criteria
 
Flow and timing Duration of follow-up: 2 years
At baseline: 130 amnestic MCI
At follow-up: 58 MCI-AD; 72 MCI-stable; D+ (disease positive) = 58; D- (disease
negative) = 72
Number included in analysis: (N = 130)
Conversion to ADD:
CSF t-tau
Sensitivity = 60.7%; specificity = 58.9% (Table 2, p 1209)
TP = 35; FP = 30; FN = 23; TN = 42 (calculated in RevMan5)
CSF p-tau
Sensitivity = 63.9%; specificity = 58.9 (Table 2, p 1209)
TP = 37; FP = 30; FN = 21; TN = 42 (calculated in RevMan5)
 
Comparative  
Notes Authors need to be contacted in order to obtain threshold's values for CSF biomarkers;
also check whether all 130 MCI participants were included in the analysis (Table 2, p
1029)
 
Leuzy 2015
Patient Sampling Study design: nested case-control study with a delayed verification design
Thirty-three participants with MCI and thirty-five participants with AD were recruited
from the Department of Geriatric Medicine, Karolinska University Hospital Huddinge,
Stockholm, Sweden. We only included data on performance of the index test to
discriminate between participants with MCI who converted to dementia and those who
remained stable.
Exclusion criteria: not reported
 
Patient characteristics and setting 33 participants with MCI diagnosed by Petersen 1999 and Winbald 2004 criteria will be
included in an updated review.
GENDER: 11 men and 10 women MCI-stable; 3 men and 9 women MCI-AD
AGE (y): 63.52 ± 8.23 MCI-stable; 62.33 ± 6.96 MCI-AD
APOE 4 carrier (%): not reported
MMSE: not reported
Education (y): 13.10 ± 3.24 MCI-stable; 13.58 ± 3.40 MCI-AD
Sources of referral: not reported
Sources of recruitment: Department of Geriatric Medicine, Karolinska University
Hospital Huddinge, Stockholm, Sweden
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Index tests CSF t-tau; CSF p-tau; CSF t-tau/ABeta1-42 ratio; CSF p-tau/ABeta1-42 ratio
CSF samples were obtained via lumbar puncture (LP) which was performed under
non-fasting conditions, between 8 and 11 a.m., with a total of 10 mL of CSF collected.
After discarding the first 0.5 mL, samples were centrifuged at 1500 × g (3000 to 4000
rpm) for 10 min at +4 ºC. Samples were then stored at –80 ºC in 1 mL portions
pending biochemical analysis, without being thawed or refrozen. Levels of CSF
biomarkers were determined using commercially available sandwich ELISAs
(Innogenetics, Ghent, Belgium).
Note: For the MCI group, levels of ABeta1-42 and t-tau were obtained for all subjects,
with p-tau181p available for 26 of 33 subjects.
Threshold: prespecified; cutoff ˃ 400 pg/mL CSF t-tau; cutoff ˃ 80 pg/mL CSF p-tau;
cutoff < 1.14 CSF ABeta1-42/t-tau ratio; cutoff < 6.5 CSF ABeta1-42/p-tau ratio
 
Target condition and reference
standard(s)
Target condition: conversion from MCI to Alzheimer’s disease
Reference standard: NINCDS-ADRDA criteria
 
Flow and timing Duration of follow-up: not reported
At baseline: 33 MCI
At follow-up: 21 MCI-stable; 12 MCI-AD
Number included in analysis: (N = 33)
Conversion to ADD:
CSF t-tau
TP = 8; FP = 7; FN = 4; TN = 14 (Table 2, p 1081)
sensitivity = 67%; specificity = 67% (calculated in Revman5)
CSF ABeta1-42/t-tau ratio
TP = 6; FP = 6; FN = 6; TN = 15 (Table 2, p 1081)
sensitivity = 50%; specificity = 71% (calculated in Revman5)
Number included in analysis: (N = 26)
Conversion to ADD:
CSF p-tau
CSF ABeta1-42/p-tau ratio
Insufficient data to create 2 X 2 tables. It was not reported how many MCI-stable and
MCI-AD were at follow-up in a group of 26 MCI with available CSF p-tau biomarkers.
 
Comparative  
Notes Authors need to be contacted in order to obtain missing data for creating 2 X 2 tables
for the CSF p-tau and CSF ABeta1-42/p-tau ratio biomarkers. Check with the authors
whether the data used in 2 X 2 tables are correctly extracted from Table 2, p 1081 for
the CSF t-tau and CSF ABeta1-42/t-tau ratio biomarkers; ask for a length of a follow-
up period.
 
Footnotes
AD: Alzheimer's disease; ADD: Alzheimer's disease dementia; FTD: fronto-temporal dementia; GDS: Global Deterioration Scale; LP: lumbar puncture;
MCI: mild cognitive impairment; MMSE: mini-mental state examination; NIA-AA: National Institute on Aging-Alzheimer’s Association ;NINDS-ADRDA:
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Performance of CSF biomarkers in early diagnosis of dementia
What is the diagnostic accuracy of CSF biomarker levels for detecting Alzheimer's disease pathology in people with mild
cognitive impairment (MCI), and identifying those MCI participants who would convert to Alzheimer’s disease dementia or
other forms of dementia over time
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Descriptive
Patient
population
Participants diagnosed with MCI at baseline using any of the Petersen criteria or CDR = 0.5 or any
16 definitions included by Matthews (Matthews 2008)
Sampling
procedure
Consecutive or random (n = 5)
Not consecutive or random (n = 3)
Unclear (n = 7)
Sources of
recruitment
University memory clinic (n = 8); European multicentre memory clinics (n = 2); inpatients (n = 2); General
Hospital memory clinic (n = 1); Research centre outpatient memory clinic (n = 1); not reported (n = 1)
Prior testing The only testing prior to performing the plasma and CSF biomarkers was the application of diagnostic criteriafor identifying participants with MCI.
MCI criteria
Petersen criteria (n = 14)
Global Deterioration Scale (GDS) (n = 1)
Index tests CSF t-tau or CSF p-tau or CSF p-tau/ABeta ratio or CSF t-tau/ABeta ratio
Reference
standard
 
NINCDS-ADRDA and/or DSM and/or ICD criteria for Alzheimer's disease dementia (n = 12); Global Dementia
Scale (GDS) & Research criteria (n = 1); CDR = 1 criteria (n = 1); not specified (n = 1)
McKeith criteria for Lewy body dementia; Lund criteria for frontotemporal dementia; and NINDS AIREN criteria
for vascular dementia
Target
condition Alzheimer’s disease dementia or any other types of dementia
Included
studies
Prospectively well-defined cohorts of MCI participants (n = 7), nested case-control studies with a prospectively
defined MCI group (n = 6) and studies with a retrospectively defined MCI group with longitudinal data (n = 2).
Fifteen studies (N = 1282 participants) were included. Number included in analysis: 1172
Quality
concerns
Patient selection and conduct of the reference standard were poorly reported. Applicability concerns were
generally low. Regarding the inclusion criteria set in the review, the majority of included studies did match the
review question: 'Could CSF t-tau and CSF t-tau/ABetaratio biomarkers identify those MCI participants with
Alzheimer’s disease pathology at baseline who would convert clinically to dementia at follow up?' However,
due to a limited number of included studies and levels of heterogeneity, it is difficult to determine to what
extent the findings from a meta-analysis can be applied to clinical practice.
Limitations Limited investigation of heterogeneity due to insufficient number of studies. There was a lack of commonthresholds.
Test
Median
percentage
converting
(range) 2
Studies Cases/participants
Median specificity
from included
studies
Sensitivity 
(95% CI)1 at
median
specificity 
Consequences in a cohort of 100
Median
percentage
converting2
Missed
cases
 
Overdiagnosed
Alzheimer's disease dementia
CSF t-tau 7 436/709 72 77 (67, 85) 37 9 18
Alzheimer's disease dementia
CSF p-tau 6 164/492 47.5 81 (64, 91.5) 37 7 33
Alzheimer's disease dementia
CSF p-tau/
ABeta ratio 5 140/433 No meta-analysis
No meta-
analysis
     
All types of dementia
CSF t-tau 4 166/319 No meta-analysis No meta-analysis
     
Investigation of heterogeneity: the planned investigations were not possible due to the limited number of studies available
for each analysis. We were unable to investigate the effect of duration of follow-up due to substantial variation in length and
reporting.
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
57 / 89
Conclusions: Given the insufficient evidence to evaluate the diagnostic value in MCI of CSF t-tau, CSF p-tau, CSF t-
tau/ABeta ratio and CSF p-tau/ABeta ratio for Alzheimer's disease dementia and other forms of dementias examined in this
review, particular attention should be paid to the risk of misdiagnosis and overdiagnosis of dementia (and therefore
overtreatment) in clinical practice. Future studies with more uniform approaches to thresholds, analysis and study conduct
may provide a more homogenous estimate than the one that has been available from the included studies we have
identified.
Footnotes
1Meta-analytic estimate of sensitivity derived from the HSROC model at a fixed value of specificity. Summary estimates of
sensitivity and specificity were not computed because the studies that contributed to the estimation of the summary ROC
curve used different thresholds.
2The median percentage converting was calculated using all the studies that reported 'conversion from MCI to
Alzheimers' disease dementia' (Table 2)
Additional tables 
1 Studies awaiting classification
Conversion from MCI to Alzheimer’s disease dementia
Study
Participants
n/N
(included in
analysis)
Index test
(number and %
of positive
tests)
Threshold 
(test abnormal)
(prespecified
Yes/No)
Number of
converters
(%) 
FP and FN
Test accuracy at
study level
Duration of follow-up
Sensitivity Specificity
*Balasa 2014 51/51
 
CSF
ABeta42/p-tau
ratio
25/51 (49%)
< 6.43
(Yes)
24/51 (47%)
FP =1; FN =0
100% 96%
41 months for MCI-AD;
30 months for MCI-
MCI
*Ewers 2012 130/130
 
CSF t-tau
65/130 (50%)
Not reported
58/130 (45%)
FP = 30; FN =
23
60.7% 58.9%
24 months
 
CSF p-tau
67/130 (51.5%)
Not reported
58/130 (45%)
FP = 30; FN =
21
63.9% 58.9%
*Leuzy 2015 33/33
CSF t-tau
15/33 (45%)
˃ 400 pg/mL(Yes)
12/33 (36%)
FP = 7; FN =
4
67% 67%
Not reported
CSF t-
tau/ABeta ratio
12/33 (36%)
< 1.14
(Yes)
12/33 (36%)
FP = 6; FN =
6
50% 71%
Conversion from MCI to all dementias
*Eckerstrom
2015 73/73
CSF p-tau
15/73 (20.5%)
73 pg/mL
(No)
27/73 (36.9%)
FP = 3; FN =
15
75% 92%
43.1 ± 23 months MCI-
stable; 33.7 ± 24
months MCI
converters
Study awaiting translation
Urakami
2004
 
Footnotes
AD: Alzheimer's disease; FN: false negative; FP: false positive; MCI: mild cognitive impairment
*Authors need to be contacted in order to obtain missing data/relevant information. Data presented are provisional.
2 Conversion from MCI to Alzheimer's disease dementia
Included studies, index test and test accuracy at study level for conversion from MCI to Alzheimer’s disease dementia
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Study
Participants
n/N
(included in
analysis)
Index test
(number and
% of positive
tests)
Threshold 
(test abnormal) (prespecified
Yes/No)
Number of
converters
(%) 
FP and FN
Test accuracy at
study level Duration of
follow-up
Sensitivity Specificity
Amlien
2013 49/39
 
CSF t-tau
9/39 (23%)
≥ 300 ng/L for age younger than
50 years; ≥ 450 ng/L for age 50
to 69 years; ≥ 500 ng/L for age
older than 70 years (Sjogren
2001)
(Yes)
9/39 (23%);
FP = 4; FN
= 4
56% 87%
mean 2.6 ± 0.5
years
(range 1.6 to 4
years)
Buchhave
2012* 137/134
CSF p-
tau/ABeta
ratio
69/134
(51%)
˂ 6.2 ng/L
(No)
72/134
(54%)
FP = 6; FN
= 9
88% 90%
median: 9.2 years
(range 4 to 12
years)
Fellgiebel
2007 16/16
CSF p-tau
12/16 (75%)
 
≥ 50 pg/mL
(No)
4/16 (25%)
FP = 8; FN
= 0
100% 33% mean 19.6 ± 9.0months
Hampel
2004 52/52
CSF t-tau
38/52 (73%)
≥ 479 ng/L
(No)
29/52
(56%);
FP = 12; FN
= 3
90% 48%
mean 8.4 ± 5.1
months
(range 2 to 24
months)
Hansson
2006* 137/134
CSF t-tau
38/134
(28%)
> 350 ng/L
(No)
57/134
(42%);
FP = 9; FN
= 28
51% 88%
 
Total sample:
median 5.2 years
(range 4.0 to 6.8
years);
MCI-AD: median:
4.3 years (range
1.1 to 6.7 years)
MCI-other
dementias:
median 4.2 years
(range 1.5 to 3
years)
CSF p-tau
50/134
(37%)
≥ 60 ng/L
(No)
57/134
(42%);
FP = 11; FN
= 18
68% 86%
CSF p-
tau/ABeta
ratio
74/134
(55%)
˂ 6.5 ng/L
(No)
57/134
(42%);
FP = 19; FN
= 2
96% 75%
Kester
2011 153/100
CSF t-tau
64/100
(64%)
> 356 pg/mL
(Yes)
42/100
(42%)
FP = 29; FN
= 7
83% 50%
median 18
months
(IQR 13 - 24)
Koivunen
2008 15/14
CSF p-tau
9/14 (64%)
≥ 70 pg/mL
(Yes)
5/14 (36%)
FP = 7; FN
= 3
40% 22%
2 yearsCSF p-
tau/ABeta
ratio
9/14 (64%)
˂ 6.5 pg/mL
(yes)
5/14 (36%)
FP = 6; FN
= 1
80% 33%
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Monge-
Argiles
2011
37/37
CSF t-tau
16/37 (43%)
≥ 77.5 pg/mL
(No)
11/37 (28%)
FP = 8; FN
= 3
73% 69%
6 months
CSF p-tau
20/37 (54%)
≥ 54.5 pg/mL
(No)
11/37 (28%)
FP = 11; FN
= 2
82% 58%
CSF p-
tau/ABeta
ratio
18/37 (49%)
0.17
(No)
11/37 (28%)
FP = 9; FN
= 2
82% 66%
CSF t-
tau/ABeta
ratio
23/37 (62%)
0.18
(No)
11/37 (28%)
FP = 13; FN
= 1
91% 50%
Palmqvist
2013 133/133
CSF t-tau
65/133
(49%)
> 87 pg/mL
(No)
52/133
(39%)
FP = 23; FN
= 10
81% 72%
mean 5.9 years
(range 3.2 to 8.8
years)CSF p-tau
46/133
(34%)
> 39 pg/mL
(No)
52/133
(39%)
FP = 11; FN
= 17
67% 86%
Parnetti
2012 90/90
CSF p-
tau/ABeta
ratio
29/90 (32%)
1074.0
(No)
32/90 (35%)
FP = 3; FN
= 6
81% 95%
maximum: 4
years; mean 3.40
± 1.01 years
Visser
2009 168/158
CSF p-tau
108/158
(68%)
≥ 51 pg/mL
(used in clinical practice) (No)
35/158
(22%)
FP = 77; FN
= 4
88% 37%
range 1 to 3 for
MCI
CSF p-tau
45/158
(28%)
≥ 85pg/mL
(> 90th percentile of controls
after correction for age)
(No)
35/158
(22%)
FP = 25; FN
= 15
57% 80%
CSF p-
tau/ABeta
ratio
77/158
(49%)
˂ 9.92 (< 10th percentile of
reference group after correction
for age) (No)
35/158
(22%);
FP = 49; FN
= 7
80% 60%
Vos 2013 231/214
CSF t-tau
93/214
(43%)
> 450 pg/mL for age less than
70 years; > 500 pg/mL for age
older than 70 years (Yes)
91/214
(42%)
FP = 28; FN
= 26
71% 77%
mean 2.5 ± 1.0
yearsCSF t-
tau/ABeta
ratio
147/214
(69%)
ABeta1–42/(240 1 [1.18 3 t-tau])
˂ 1.0
(Yes)
91/214
(42%)
FP = 60; FN
= 4
96% 51%
Footnotes
AD: Alzheimer's disease; FN: false negative; FP: false positive; MCI: mild cognitive impairment
*Studies involved the same participants. Only Hansson 2006 is included in the meta-analysis
3 Conversion from MCI to All dementia
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Included studies, index test and test accuracy at study level for conversion from MCI to All dementias
Study
Participants
n/N
(included in
analysis)
Index test
(Number
and % of
positive
tests)
Threshold 
(test abnormal) (pre-
specified Yes / No)
Number of
converters
(%) 
FP and FN
Test accuracy at
study level
Duration of follow-up
Sensitivity Specificity
Eckerstrom
2010 42/42
CSF t-tau
15/42
(36%)
≥ 500 ng/L
(No)
21/42 (50%)
FP = 1
FN = 7
67% 95%
Total sample: 19.6 ± 9.0
months; MCI-MCI: 19.5 ±
9.3 months; MCI-
progressive: 17.6 ± 8.8
months (4/8 MCI-AD: 23.7
± 2.0 months)
Galluzzi
2010 90/64
 
CSF t-tau
24/64
(37.5%)
> 450 pg/mL for subjects
with an age range
between 51 and 70
determined; > 500 pg/mL
for subjects with an age
range between 71 and 93
(Yes)
 
34/64 (53%)
FP = 5
FN = 15
56% 83%
Total sample: 8.4 ± 5.1
months (range 2 to 24
months); follow-up interval
for converters was 9.6 ±
5.4, and for non-
converters 7.0 ± 4.3
months
Hansson
2006 137/134
 
CSF t-tau
38/134
(28%)
 
> 350 pg/mL
(No)
78/134
(58%)
FP = 5
FN = 45
42% 91%
Total sample: median 5.2
years (range 4.0 to 6.8);
MCI-AD: median: 4.3
years (range 1.1 to 6.7);
MCI-other dementias:
median 4.2 (1.5 to 6.3)
Herukka
2007 79/79
CSF t-tau
43/79
(54%)
 
> 400 pg/mL (Yes)
33/79 (42%)
FP = 17
FN = 7
79% 63%
Mean 3.52 ± 1.95 years in
MCI converters; mean
4.56 ± 3.09 years in MCI-
stable
Footnotes
AD: Alzheimer's disease; FN: false positive; FP: false negative; MCI: mild cognitive impairment
References to studies
Included studies 
Amlien 2013
Published and unpublished data [CRSSTD: 5321633]
* Amlien IK, Fjeli AM, Walhovd KB, Selnes P, Stenset V, Grambaite R, at al. Mild cognitive impairment: cerebrospinal fluid
tau biomarker pathologic levels and longitudinal changes in white matter integrity. Radiology 2013;266:295-303. [CRSREF:
5321634]
Buchhave 2012
[CRSSTD: 5321635]
* Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42,
but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of General
Psychiatry 2012;69(1):98-106. [CRSREF: 5321636]
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93. [CRSREF: 5321637]
Eckerstrom 2010
[CRSSTD: 5321638]
* Eckerström C, Andreasson U, Olsson E, Rolstad S, Blennow K, Zetterberg H, et al. Combination of hippocampal volume
and cerebrospinal fluid biomarkers Improves predictive value in mild cognitive impairment. Dementia and Geriatric Cognitive
Disorders 2010;29:294-300. [CRSREF: 5321639]
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93. [CRSREF: 5321640]
Wallin A, Göthlin M, Gustavsson M, Zetterberg H. Eckerström C, Blennow K, et al. Progression from mild to pronounced MCI
Is not associated with cerebrospinal fluid biomarker deviations. Dementia and Geriatric Cognitive Disorders 2011;32:193-7.
[CRSREF: 5321641]
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
61 / 89
Fellgiebel 2007
[CRSSTD: 5321642]
* Fellgiebel A, Scheurich A, Bartenstein P, Müller MJ. FDG-PET and CSF phospho-tau for prediction of cognitive decline in
mild cognitive impairment. Psychiatry Research: Neuroimaging 2007;155:167-71. [CRSREF: 5321643]
Galluzzi 2010
Published and unpublished data [CRSSTD: 5321644]
* Galluzzi S, Geroldi C, Ghidoni R, Paghera B, Amicucci G, Bonetti M, et al. The new Alzheimer's criteria in a naturalistic
series of patients with mild cognitive impairment. Journal of Neurology 2010;257(12):2004-14. [CRSREF: 5321645]
Hampel 2004
[CRSSTD: 5321646]
* Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, at al. Value of CSF ß-amyloid1-42 and tau as
predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry 2004;9:705-10. [CRSREF:
5321647]
Hansson 2006
Published and unpublished data [CRSSTD: 5321648]
* Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and
incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 2006;5:228-34.
[CRSREF: 5321649]
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93. [CRSREF: 5321650]
Herukka 2007
[CRSSTD: 5321651]
Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Ab42 and tau or phosphorylated tau and prediction of progressive
mild cognitive impairment. Neurology 2005;64:1294-7. [CRSREF: 5321652]
Herukka SK, Hallikainen M, Tervo S, Helisalmi S, Tapiola T, Soininen T, et al. Cerebrospinal fluid Aβ42, tau and
phosphorylated tau predict progression in patients with cognitive impairment. Research and Practice in Alzheimer's disease
2006;11:245-50. [CRSREF: 5321653]
* Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T. CSF Aß42, tau and phosphorylated tau, APOE ε4
allele and MCI type in progressive MCI. Neurobiology of Aging 2007;28:507-14. [CRSREF: 5321654]
Herukka SK, Pennanen C, Soininen H, Pirttila T. CSF Aβ42, tau and phosphorylated tau correlate with medial temporal lobe
atrophy. Journal of Alzheimer's Disease 2008;14:51-7. [CRSREF: 5321655]
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93. [CRSREF: 5321656]
Seppala TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in
Alzheimer’s disease. Journal of Alzheimer's Disease 2011;25:583-94. [CRSREF: 5321657]
Kester 2011
[CRSSTD: 5321658]
* Kester MI, Verwey NA, Van Elk EJ, Blankenstein MA, Scheltens P, Van der Flier WM. Progression from MCI to AD:
predictive value of CSF Aβ42 is modified by APOE genotype. Neurobiology of Aging 2011;32(8):1372-8. [CRSREF:
5321659]
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93. [CRSREF: 5321660]
Koivunen 2008
[CRSSTD: 5321661]
* Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka S-K, Jauhianen AM, et al. PET amyloid ligand [11C]PIB uptake and
cerebrospinal fluid β-amyloid in mild cognitive Impairment. Dementia and Geriatric Cognitive Disorders 2008;26:378-83.
[CRSREF: 5321662]
Monge-Argiles 2011
[CRSSTD: 5321663]
* Monge-Argiles JA, Munoz-Ruiz C, Pampliega-Perez A, Gomez-Lopez MJ, Sanchez-Paya J, Rodriguez-Borja E, et al.
Biomarkers of Alzheimer's disease in the cerebrospinal fluid of Spanish patients with mild cognitive impairment.
Neurochemical Research 2011;36:986-93. [CRSREF: 5321664]
Monge-Argiles JA, Sanchez-Payab J, Munoz-Ruiz C, Pampliega-Perez A, Gomez-Lopez MJ, Borja ER, et al. Patients with
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
62 / 89
mild cognitive impairment and a reduced CSF Aβ1-42 protein progress rapidly to Alzheimer’s disease. Neurologia 2012;
27(1):28-33. [CRSREF: 5321665]
Palmqvist 2012
[CRSSTD: 5321666]
Hertzel J, Minthono L, Zetterberg H, Vanmechelend E, Blcnnowc K, Hanssonllb O. Evaluation of CSF biomarkers as
predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. Journal of Alzheimer's Disease 2010;21:1119-28.
[CRSREF: 5321667]
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93. [CRSREF: 5321668]
* Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg Z, Blennow K, at al. Comparison of brief cognitive tests and CSF
biomarkers in predicting Alzheimer’s disease in mild cognitive impairment: six-year follow-up study. PLoS ONE 2012;
7(6):e38639. [CRSREF: 5321669; DOI: 10.1371/journal.pone.0038639]
Parnetti 2012
[CRSSTD: 5321670]
* Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, et al. Performance of Aβ1-40, Aβ1-42, total
tau,and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. Journal of
Alzheimer's Disease 2012;29:229-38. [CRSREF: 5321671]
Visser 2009
Published and unpublished data [CRSSTD: 5321672]
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93. [CRSREF: 5321673]
* Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, et al. Prevalence and prognostic value of CSF
markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the
DESCRIPA study: a prospective cohort study. Lancet Neurology 2009;8:619-27. [CRSREF: 5321674]
Vos 2013
Published and unpublished data [CRSSTD: 5321675]
* Vos SJB, Van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund L-O, et al. Prediction of Alzheimer disease in subjects
with amnestic and nonamnestic MCI. Neurology 2013;80:1-9. [CRSREF: 5321676]
Excluded studies 
Desikan 2011
[CRSSTD: 5321677]
* Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, et al. Amyloid-β associated volume loss
occurs only in the presence of phospho-tau. Annals of Neurology 2011;70:657-61. [CRSREF: 5321678]
Forlenza 2010
[CRSSTD: 5321679]
* Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, et al. Clinical and biological predictors of
Alzheimer’s disease inpatients with amnestic mild cognitive impairment. Revista Brasileira de Psiquiatria 2010;32(3):216-22.
[CRSREF: 5321680]
Holland 2012
[CRSSTD: 5321681]
* Holland D, Desikan RS, Dale AM, McEvoy LK; Alzheimer’s Disease Neuroimaging Initiative. Rates of decline in Alzheimer
Disease decrease with age. PLOS One 2012;7(8):e42325. [CRSREF: 5321682; DOI: 10.1371/journal.pone.0042325]
Ivanoiu 2005
[CRSSTD: 5321683]
* Ivanoiu A, Sindic CJ. Cerebrospinal fluid tau protein and amyloid β42 in mild cognitive impairment: prediction of progression
to Alzheimer’s disease and correlation with the neuropsychological examination. Neurocase 2005;11(1):32-9. [CRSREF:
5321684]
Jack 2011
[CRSSTD: 5321685]
* Jack CR, Vemuri P, Wiste BA, Weigand SD, Aisen PS, Trojanowski J, et al. Evidence for ordering of Alzheimer disease
biomarkers. Archives of Neurology 2011;68(12):1526-35. [CRSREF: 5321686]
Jagust 2009
[CRSSTD: 5321687]
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
63 / 89
* Jagust WJ, Landau SM, Shaw M, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in
aging and dementia. American Academy of Neurology 2009;73:1193-9. [CRSREF: 5321688]
Lanari 2009
[CRSSTD: 5321689]
* Lanari A, Parnetti L. Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive Impairment:
4-year follow-up in a routine clinical setting. Scientific World 2009;9:961-6. [CRSREF: 5321690]
Landau 2010
[CRSSTD: 5321691]
Davatzikosa C, Bhatta P, Shawb LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF
biomarkers, and pattern classification. Neurobiology of Aging 2011;32:2322.e19-2322.e27. [CRSREF: 5321692]
Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, et al. Body mass index is associated with biological
CSF markers of core brain pathology of Alzheimer’s disease. Neurobiology of Aging 2012;33:1599-608. [CRSREF: 5321693]
Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack Jr. CR, et al. Prediction of conversion from mild cognitive
impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance.
Neurobiology of Aging 2012;33:1203-14. [CRSREF: 5321694]
Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE. Utility of combinations of biomarkers,
cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in
the Alzheimer’s Disease Neuroimaging Initiative. Archives of General Psychiatry 2011;68(9):961-9. [CRSREF: 5321695]
* Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and
decline in mild cognitive impairment. Neurology 2010;75:230-8. [CRSREF: 5321696]
Maruyama 2004
[CRSSTD: 5321697]
* Maruyama M, Matsui T, Tanji H, Nemoto M, Tomita N, Ootsuki M, et al. Cerebrospinal fluid tau protein and periventricular
white matter lesions in patients with mild cognitive impairment. Archives of Neurology 2004;61:716-20. [CRSREF: 5321698]
Maruyama 2004b
[CRSSTD: 5321699]
* Maruyama M, Matsui T, Tanji H, Ootsuki M, Nemoto M, Tomita N, et al. Diagnosing the mild cognitive impairment stage of
Alzheimer's disease. Psychiatria et Neurologia Japonica 2004;106(3):269-80. [CRSREF: 5321700]
Mattsson 2012
[CRSSTD: 5321701]
* Mattsson N, Porteliusa E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, et al. Longitudinal cerebrospinal fluid
biomarkers over four years in mild cognitive impairment. Journal of Alzheimer's Disease 2012;30:767-78. [CRSREF:
5321702]
Nordlund 2010
[CRSSTD: 5321703]
* Nordlund A, Rolstad S, Klang O, Edman A, Hansen S, Wallin A. Two-year outcome of MCI subtypes and aetiologies in the
Goteborg MCI study. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81:541-6. [CRSREF: 5321704]
Okamura 2002
[CRSSTD: 5321705]
* Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, et al. Combined analysis of CSF tau levels and
[123I]Iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer’s Disease.
American Journal of Psychiatry 2002;159:474–6. [CRSREF: 5321706]
Okonkwo 2011
[CRSSTD: 5321707]
* Okonkwo OC, Mielke MM, Griffith HR, Moghekar AR, O’Brien RJ, Shaw LM, et al. Cerebrospinal fluid profiles and
prospective course and outcome in patients with amnestic mild cognitive impairment. Archives of Neurology 2011;
68(1):113-9. [CRSREF: 5321708]
Pereira 2010
[CRSSTD: 5321709]
* Pereira FS, Yassuda MS, Olivira AM, Diniz BS, Radanovic M, Talib LL, et al. Profiles of functional deficits in mild cognitive
impairment and dementia: benefits from objective measurement. International Neuropsychological Society 2010;16:297-305.
[CRSREF: 5321710]
Perneczky 2011
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
64 / 89
[CRSSTD: 5321711]
* Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H, et al. CSF soluble amyloid precursor proteins in
the diagnosis of incipient Alzheimer disease. Neurology 2011;77:35-8. [CRSREF: 5321712]
Riemenschneider 2002
[CRSSTD: 5321713]
* Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-
amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Archives of Neurology 2002;
59(11):1729-34. [CRSREF: 5321714]
Samtani 2012
[CRSSTD: 5321715]
* Samtani MN, Raghavan N, Shi Y, Novak G, Farnum M, Lobanov V, et al. Disease progression model in subjects with mild
cognitive impairment from the Alzheimer’s disease neuroimaging initiative: CSF biomarkers predict population subtypes.
British Journal of Clinical Pharmacology 2012;75(1):146-61. [CRSREF: 5321716]
Schneider 2010
[CRSSTD: 5321717]
* Schneider LS, Kennedy RE, Cutter GR; Alzheimer’s Disease Neuroimaging Initiative. Requiring an amyloid-b1-42
biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials.
Alzheimers & Dementia 2010;6:e367-77. [CRSREF: 5321718]
Shaw 2009
[CRSSTD: 5321719]
* Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker
signature in Alzheimer’s disease neuroimaging initiative subjects. Annals of Neurology 2009;65:403-13. [CRSREF: 5321720]
Sluimer 2010
[CRSSTD: 5321721]
* Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, Van der Flier WM, et al. Whole-brain atrophy rate and
CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiology of Aging 2010;31:758-64. [CRSREF: 5321722]
Snider 2009
[CRSSTD: 5321723]
* Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C. Cerebrospinal fluid biomarkers and rate of cognitive decline in
very mild dementia of the Alzheimer type. Archives of Neurology 2009;66(5):638-45. [CRSREF: 5321724]
Van Harten 2012
[CRSSTD: 5321725]
* Van Harten AC, Visser PJ, Pijnenburg YAL, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Aß42
is the best predictor of clinical progression in patients with subjective complaints. Alzheimers & Dementia 2013;9:481-7.
[CRSREF: 5321726]
Verwey 2008
[CRSSTD: 5321727]
* Verwey NA, Bouwman FH, Van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA. Variability in longitudinal
cerebrospinal fluid tau and phosphorylated tau measurements. Clinical Chemistry and Laboratory Medicine 2008;
46(9):1300-4. [CRSREF: 5321728]
Walhovd 2010
[CRSSTD: 5321729]
* Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, et al. Combining MR imaging, positron-
emissiontomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. American Journal of
Neuroradiology 2010;31(2):347-54. [CRSREF: 5321730]
Wang 2012
[CRSSTD: 5321731]
* Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, Morris JC, et al. Cerebrospinal fluid proteins predict longitudinal
hippocampal degeneration in early-stage dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders
2012;26:314-21. [CRSREF: 5321732]
Westman 2012
[CRSSTD: 5321733]
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
65 / 89
* Westman E, Muehlboeck J-S, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and
prediction of mild cognitive impairment conversion. Neurolmage 2012;62:229-38. [CRSREF: 5321734]
Yang 2012
[CRSSTD: 5321735]
* Yang X, Tan MZ, Qiu A. CSF and brain structural imaging markers of the Alzheimer’s pathological cascade. PLOS One
2012;7(12):e47406. [CRSREF: 5321736]
Studies awaiting classification 
Balasa 2014
[CRSSTD: 5321737]
Balasa M, Sanchez-Valle R, Antonell A, Bosch B, Olives J, Rami L, et al. Usefulness of biomarkers in the diagnosis and
prognosis of early-onset cognitive impairment. Journal of Alzheimer's Disease 2014;40(4):919-27. [CRSREF: 5321738]
Eckerstrom 2015
[CRSSTD: 5321739]
Eckerström C, Olsson E, Klasson N, Berge J, Nordlund A, Bjerke M, et al. Multimodal prediction of dementia with up to 10
years follow up: the Gothenburg MCI study. Journal of Alzheimer's disease 2015;44(1):205-14. [CRSREF: 5321740]
Ewers 2012
[CRSSTD: 5321741]
Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, et al; North American Alzheimer's Disease
Neuroimaging Initiative (ADNI). Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia
based upon biomarkers and neuropsychological test performance. Neurobiology of Aging 2012;33(7):1203-14. [CRSREF:
5321742]
Leuzy 2015
[CRSSTD: 5321743]
Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and diagnostic accuracy of [11C]PIB PET and
cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer's disease. Journal of
Alzheimer's Disease 2015;45(4):1077-88. [CRSREF: 5321744]
Ongoing studies 
Other references
Additional references 
Albert 2011
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: recommendation from the National Institute on Ageing and Alzheimer’s Association workgroup.
Alzheimers & Dementia 2011;7(3):270-9.
Arevalo-Rodriguez 2015
Arevalo-Rodriguez I, Smailagic N, Roqué i Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-Mental State
Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment
(MCI). Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No.: CD010783 DOI:
10.1002/14651858.CD010783.pub2.
Beckett 2010
Beckett LA, Harvey DJ, Gamst A, Donohueb M, Kornak J, Zhang H, et al. The Alzheimer’s Disease Neuroimaging Initiative:
annual change in biomarkers and clinical outcomes. Alzheimers & Dementia 2010;6:257-64.
Beynon 2013
Beynon R, Leeflang MM, McDonald S, Eisinga A, Mitchell RL, Whiting P, et al. Search strategies to identify diagnostic
accuracy studies in MEDLINE and EMBASE. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: MR000022
DOI: 10.1002/14651858.MR000022.pub3.
Billingsley 1997
Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule
interaction, intracellular trafficking and neurodegeneration. Biochemical Journal 1997;323(3):577-91.
Blennow 2003
Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology 2003;2(10):605-13.
Bossuyt 2008
Bossuyt PM, Leeflang MM. Chapter 6: Developing criteria for including studies. Cochrane Handbook for Systematic Reviews
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
66 / 89
of Diagnostic Test Accuracy 2008:http://methods.cochrane.org/sdt/.
Bourne 2007
Bourne J. Improving services and support for people with dementia. National Audit Office 2007.
Boxer 2005
Boxer A, Miller B. Clinical features of frontotemporal dementia. Alzheimer Disease & Associated Disorders 2005;19:S3-S6.
Bruscoli 2004
Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International
Psychogeriatrics 2004;16:129-40.
Davison 2003
Davison AC. Statistical Models. Cambridge University Press, 2003.
DSMIII 1987
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American
Psychiatric Association 1987. 3rd revised edition.
DSMIV 1994
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American
Psychiatric Association 1994. 4th edition.
Dubois 2007
Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis
of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurology 2007;6(8):734-6.
Dubois 2010
Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of
Alzheimer's disease: a new lexicon. Lancet Neurology 2010;9(11):1118-27.
Dubois 2014
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo L, Blenonow K, et al. Advancing research diagnostic criteria for
Alzheimer's disease: the IWG-2 criteria. Lancet Neurology 2014;13:614-29.
Ferri 2005
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus
study. Lancet 2005;366(9503):2112-7.
Geslani 2005
Geslani D, Tierney M, Herrmann N, Szalai J. Mild cognitive impairment: an operational definition and its conversion rate to
Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2005;19:383-9.
Knapp 2007
Knapp M, Prince M. Dementia UK: A report to the Alzheimer's Society on the prevalence and economic cost of dementia in
the UK produced by King's College London and London School of Economics. London (UK): Alzheimer's Society; 2007.
Knopman 2001
Knopman D, DeKosky S, Cummings J, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia
(an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology.
Neurology 2001;56(9):1143-53.
Knottnerus 2002
Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ 2002;324(7335):477-80.
LMG 1994
Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology,
Neurosurgery, and Psychiatry 1994;57(4):416-8.
Mandelkow 1998
Mandelkow EM, Mandelkow E. Tau in Alzheimer’s disease. Trends in Cell Biology 1998;8:4257.
Mason 2010
Mason SE, McShane R, Ritchie CW. Diagnostic tests for Alzheimer's disease: rationale, methodology, and challenges.
International Journal of Alzheimer’s Disease 2010;2010:Article ID 972685.
Matthews 2008
Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C. Two-year progression from mild cognitive impairment to
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
67 / 89
dementia: to what extent do different definitions agree? Journal of the American Geriatrics Society 2008;56(8):1424-33.
Matthews 2009
Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at
death in the Medical Research Council Cognitive Function and Ageing study. PLOS Medicine 2009;6:e1000180.
Mattsson 2009
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer
disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93.
McKeith 1996
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and
pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Neurology 1996;47(5):1113-24.
McKeith 2005
McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy
bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72.
McKhann 1984
McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of
the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on
Alzheimer's disease. Neurology 1984;34(7):939-44.
Molinuevo 2014
Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, et al. The clinical use of cerebrospinal
fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers
Standardisation Initiative. Alzheimers & Dementia 2014;10:808-17.
Morris 1993
Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
MRC CFAS 2001
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological
correlates of late-onset dementia in a multicentre, community-based population in England and Wales.. Lancet 2001;
357(9251):169-75.
Neary 1998
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on
clinical diagnostic criteria. Neurology 1998;51:1546-54.
Noel-Storr 2013
Noel-Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. Systematic review of the body of evidence for use
of biomarkers in the diagnosis of dementia. Alzheimers & Dementia 2013;9(3):e96-e105.
Noel-Storr 2014
Noel-Storr AH, McCleeery JM, Richard E, Ritchie C, Flicker L, Cullum S, et al. Reporting standards for studies of diagnostic
test accuracy in dementia. Neurology 2014;83:1-10.
Okello 2009
Okello A, Koivunen J, Edison P, Archer HA, Turkheimer F, Nagren K, et al. Conversion of amyloid positive and negative MCI
to AD over 3 years: an 11C-PIB PET study. Neurology 2009;73(10):754-60.
Petersen 1999
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization
and outcome. Archives of Neurology 1999;56:303-8.
Petersen 2004
Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004;256(3):183-94.
Petersen 2009
Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later.
Archives of Neurology 2009;66(12):1447-55.
Petersen 2010
Petersen R, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative
(ADNI): clinical characterization. Neurology 2010;74(3):201-9.
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
68 / 89
Prince 2013
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and
metaanalysis. 2013;9(1):63-75.e2.
Quadas-2
University of Bristol. Quadas-2. www.bris.ac.uk/quadas/quadas-2 (accessed prior to 18 February 2017).
Quinn 2014
Quinn TJ, Fearon P, Noel-Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on COgnitive Decline in the
Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database of Systematic
Reviews 2014, Issue 4. Art. No.: CD010079 DOI: 10.1002/14651858.CD010079.pub2.
Reisberg 1982
Reisberg B, Ferris, SH, De Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative
dementia. American Journal of Psychiatry 1982;139(9):1136–9.
Ritchie 2011
Ritchie C, Masters CL, Mason SE, Li QX, McShane R. Plasma and CSF Abeta for the longitudinal prediction of Alzheimer's
disease dementia and other dementias in people with cognitive decline but no dementia. Cochrane Database of Systematic
Reviews 2011, Issue 1. Art. No.: CD008782 DOI: 10.1002/14651858.CD008782.pub3.
Ritchie 2014
Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta
for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD008782 DOI: 10.1002/14651858.CD008782.pub4.
Ritchie 2016
Ritchie CW, Molinuevo JL, Truyen L, Saltin A, Van der Geyten S, Lovestone S; European Prevention of Alzheimer's
Dementia (EPAD) Consortium. Development of interventions for the secondary prevention of Alzheimer's dementia: the
European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry 2016;3(2):179-86.. [DOI:
10.1016/S2215-0366(15)00454-X]
Roman 1993
Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria
for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993;43(2):250-60.
SAS Institute 2011
SAS Version 9.2 [Computer program]. SAS Institute. Cary, NC, USA, 2011.
Savva 2009
Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, neuropathology, and dementia. New
England Journal of Medicine 2009;360(22):230-9.
Shoji 1992
Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid beta protein by
normal proteolytic processing. Science 1992;258(5079):126-9.
Shoji 2001
Shoji M, Kanai M. Cerebrospinal fluid Ab40 and Ab42: natural course and clinical usefulness. Journal of Alzheimer's Disease
2001;3(3):313-21.
Shoji 2002
Shoji M, Matsubara E, Murakami T, Manabe Y, Abe K, Kanai M, et al. Cerebrospinal fluid tau in dementia disorders: a large
scale multicenter study by a Japanese study group. Neurobiology of Aging 2002;23(3):363-70.
Smailagic 2015
Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. 18F-FDG PET for the early diagnosis of
Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of
Systematic Reviews 2015, Issue 1. Art. No.: CD010632 DOI: 10.1002/14651858.CD010632.pub2.
Urakami 2004
Urakami K, Saito K, Seishima M, Nakashima K. Apolipoprotein A-I and E in cerebrospinal fluid. Nihon Rinsho. Japanese
Journal of Clinical Medicine 2004;62 Suppl 11:176-8.
Visser 2006
Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology
2006;67:1201-07.
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
69 / 89
Whiting 2011
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality
assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155:529-36.
Wilmo 2010
Wilmo A, Prince M. World Alzheimer Report 2010: The global economic impact of dementia.
www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf (accessed prior to 17 Feb 2017).
Winbald 2004
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment - beyond controversies,
towards a consensus: report of the international working group on mild cognitive impairment. Journal of Internal Medicine
2004;256:240-6.
World Health Organization 2010
World Health Organization. International statistical classification of diseases and related health problems (ICD-10 Version:
2010). apps.who.int/classifications/icd10/browse/2010/en (accessed 9 January 2013):1-195.
Zhang 2014
Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, at al. 11C-PIB-PET for the early diagnosis of
Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of
Systematic Reviews 2014, Issue 7. Art. No.: CD010386 DOI: 10.1002/14651858.CD010386.
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Data and analyses 
Data tables by test
Test StudiesParticipants
1 CSF t-tau conversion to AD dementia 7 709
2 CSF p-tau conversion to AD dementia 6 492
3 CSF p-tau/ABeta ratio to AD dementia5 433
4 CSF t-tau conversion to All dementias 4 319
Figures
Figure 1
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Caption
Study flow diagram
Note: a top-up search performed in December 2015 revealed 6134 records
85 records retained after de-duplication and assessment by one experienced reviewer
81 records excluded after further assessment performed by two review authors
4 studies identified for possible inclusion (Characteristics of studies awaiting classification)
Figure 2
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Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 3
Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 4 (Analysis 1) 
Caption
Forest plot of 1 CSF t-tau conversion to AD dementia.
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Figure 5 (Analysis 1) 
Caption
Summary ROC Plot of 1 CSF t-tau conversion to AD dementia.
Figure 6
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Caption
Post-test probability plots (Analysis 1): Conversion from MCI to Alzheimer’s disease for CSF t-tau as a diagnostic test
Figure 7 (Analysis 2) 
Caption
Forest plot of 2 CSF p-tau conversion to AD dementia.
Figure 8 (Analysis 2) 
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Caption
Summary ROC Plot of 2 CSF p-tau conversion to AD dementia.
Figure 9
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Caption
Post-test probability plots (Analysis 2): Conversion from MCI to Alzheimer’s disease for CSF p-tau as a diagnostic test
Figure 10 (Analysis 3) 
Caption
Forest plot of 3 CSF p-tau/ABeta ratio to AD dementia.
Figure 11 (Analysis 3) 
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Caption
Summary ROC Plot of 3 CSF p-tau/ABeta ratio to AD dementia.
Figure 12 (Analysis 4) 
Caption
Forest plot of 4 CSF t-tau conversion to all forms of dementia.
Figure 13 (Analysis 4) 
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Caption
Summary ROC Plot of 4 CSF t-tau conversion to All dementias.
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Feedback 
Appendices 
1 Sources searched and search strategies
The MEDLINE search strategy below was created to optimise sensitivity. The strategy utilises a number of concepts:
Concept A: lines 1 to 21 health condition/s of interest
Concept B: lines 23 to 42 what is being measured by the index test/s/the index test/s
Concept C: lines 44 to 49 method of measurement (i.e. CSF)
The main yield is created by combining A AND B AND C
However, in order to try to capture those records that perhaps do not mention one or more of the three concepts above,
some additional combinations were added to the strategy. For example: In the MEDLINE strategy below, lines 51 and 52
(which identify records in Medline with the dementia MeSH subheading of diagnosis and those with a subheading of
cerebrospinal fluid) were combined with the concept for the index test(s). This approach identified unique records and an
examination of the first 50 of these records resulted in two further citations for possible inclusion within the review.
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Source
Search strategy Hits
retrieved
1. MEDLINE In-process and
other non-indexed citations
and MEDLINE 1946 to
present (Ovid SP)
1. exp Dementia/
2. Cognition Disorders/
3. (alzheimer* or dement* or AD or lewy* or VaD or frontotemporal or 'vascular
cognit* impair*').ti,ab.
4. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
5. (forgetful* or confused or confusion).ti,ab.
6. MCI.ti,ab.
7. ACMI.ti,ab.
8. ARCD.ti,ab.
9. SMC.ti,ab.
10. CIND.ti,ab.
11. BSF.ti,ab.
12. AAMI.ti,ab.
13. LCD.ti,ab.
14. QD.ti,ab.
15. AACD.ti,ab.
16. MNCD.ti,ab.
17. MCD.ti,ab.
18. (nMCI or aMCI or mMCI).ti,ab.
19. ('N-MCI' or 'A-MCI' or 'M-MCI').ti,ab.
20. 'Petersen”.ab.
21. ((CDR adj2 '0.5') or ('clinical dementia rating' adj3 '0.5')).ab.
22. or/1-21
23. (neurofibril* adj3 tangle*).ti,ab.
24. (neurofilament adj3 protein*).ti,ab.
25. (neuropil adj3 thread*).ti,ab.
26. ((senile or amyloid or neuritic) adj3 plaque*).ti,ab.
27. Neuropil Threads/
28. Senile Plaques/
29. exp Neurofibrils/
30. Neurofilament Proteins/
31. tau Proteins/
32. tau*.ti,ab.
33. hyperphosphorylation.ti,ab.
34. pTau181.ti,ab.
35. *peptide fragments/cf
36. pTau*.ti,ab.
37. ('t-tau*' or 'p-tau*').ti,ab.
38. (innotest or inno-bia or Alzbio3).ti,ab.
39. ((abeta* or ab42 or ab40 or 'amyloid-beta' or 'beta-amyloid' or 'a?42' or 'a?40' or
'a beta') adj4 (ratio or ratios)).ti,ab.
40. ('phospho-tau*' or 'total-tau*').ti,ab.
41. or/23-40
42. (cerebrospinal fluid* or csf or 'spinal fluid*').ti,ab.
43. (blood or plasma).ti,ab.
 
July
2012:
7718
Jan
2013:
480
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44. Cerebrospinal Fluid/
45. Blood-Brain Barrier/
46. or/42-45
47. (cf or bl or di or du).fs.
48. or/46-47
49. 48 and 41 and 22
50. exp *Dementia/cf [Cerebrospinal Fluid]
51. exp Dementia/di [Diagnosis]
52. cf.fs.
53. 41 and 51 and 52
54. Cerebrospinal Fluid Proteins/
55. Biological Markers/cf [Cerebrospinal Fluid]
56. or/54,55
57. 56 and 22 and 41
58. or/49,50,53,57
59. (animals not (humans and animals)).sh.
60. 58 not 59
2. Embase
1980 to 2012 week 29 (Ovid
SP)
 
1. dement*.ti.
2. alzheimer*.ti.
3. (AD or VaD or lewy or frontotemporal or 'vascular cognit* impair*').ti.
4. Dementia/di
5. dementia/ep [Epidemiology]
6. (('conversion to' or 'conversion from') adj4 (dement* or alzheimer* or AD or lewy or
VaD or 'vascular cognit* impair*')).ab.
7. ((endpoint* or 'end point*' or outcome*) adj5 (dement* or alzheimer* or AD or VaD
or lewy)).ab.
8. (predict* adj5 (dement* or alzheimer* or AD or VaD or lewy or 'vascular cognit*
impair*')).ab.
9. ((convert or converted) adj4 (dement* or alzheimer* or AD or lewy or VaD or
'vascular cognit* impair*')).ab.
10. (progress* adj5 (dement* or alzheimer* or AD or VaD or lewy or 'vascular cognit*
impair*')).ab.
11. or/1-10
12. exp dementia/
13. (alzheimer* or dement* or AD or lewy* or VaD or frontotemporal or 'vascular
cognit* impair*').ti,ab.
14. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
15. (forgetful* or confused or confusion).ti,ab.
16. MCI.ti,ab.
17. ACMI.ti,ab.
18. ARCD.ti,ab.
19. SMC.ti,ab.
20. CIND.ti,ab.
21. BSF.ti,ab.
22. AAMI.ti,ab.
23. LCD.ti,ab.
24. QD.ti,ab.
 
July
2012:
3692
Jan
2013:
732
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25. AACD.ti,ab.
26. MNCD.ti,ab.
27. MCD.ti,ab.
28. (nMCI or aMCI or mMCI).ti,ab.
29. ('N-MCI' or 'A-MCI' or 'M-MCI').ti,ab.
30. 'Petersen criteria'.ab.
31. ((CDR adj2 '0.5') or ('clinical dementia rating' adj3 '0.5')).ab.
32. (neurofibril* adj3 tangle*).ti,ab.
33. (neurofilament adj3 protein*).ti,ab.
34. (neuropil adj3 thread*).ti,ab.
35. ((senile or amyloid or neuritic) adj3 plaque*).ti,ab.
36. neuropil thread/
37. senile plaque/
38. neurofilament/
39. neurofilament protein/
40. or/12-39
41. (cerebrospinal fluid* or csf or 'spinal fluid*').ti,ab.
42. (blood or plasma).ti,ab.
43. cerebrospinal fluid/
44. blood brain barrier/
45. or/41-44
46. tau protein/
47. tau.ti,ab.
48. hyperphosphorylation.ti,ab.
49. pTau181.ti,ab.
50. tau181.ti,ab.
51. peptide fragment/
52. ('abeta*/tau' and ratio).ab.
53. pTau*.ti,ab.
54. ('t-tau*' or 'p-tau*').ti,ab.
55. (innotest or inno-bia or Alzbio3).ti,ab.
56. ((abeta* or ab42 or ab40 or 'amyloid-beta' or 'beta-amyloid' or (amyloid and 'β')
or 'aβ' or 'aβ42' or 'aβ40' or 'a beta') adj4 ratio).ti,ab.
57. ('phospho-tau*' or 'total-tau*').ti,ab.
58. tau231.ti,ab.
59. or/46-58
60. 40 and 45 and 59
61. sensitivit*.ab.
62. specificit*.ab.
63. (ROC or 'receiver operat*').ab.
64. area under the curve/
65. ('Area under curve' or AUC).ab.
66. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
67. sROC.ab.
68. accura*.ti,ab.
69. (likelihood adj3 (ratio* or function*)).ab.
70. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
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71. ((true or false) adj3 (positive* or negative*)).ab.
72. ((positive* or negative* or false or true) adj3 rate*).ti,ab.
73. reproducibility/
74. diagnos*.ti.
75. diagnostic accuracy/
76. or/61-75
77. 11 and 59 and 76
78. 60 or 77
3. PsycINFO
1806 to July week 1 2012
(Ovid SP)
 
1. dement*.ti,ab.
2. alzheimer*.ti,ab.
3. (AD or VaD or lewy or frontotemporal or 'vascular cognit* impair*').ti,ab.
4. exp Dementia/
5. (('conversion to' or 'conversion from') adj4 (dement* or alzheimer* or AD or lewy or
VaD or 'vascular cognit* impair*')).ab.
6. ((endpoint* or 'end point*' or outcome*) adj5 (dement* or alzheimer* or AD or VaD
or lewy)).ab.
7. (predict* adj5 (dement* or alzheimer* or AD or VaD or lewy or 'vascular cognit*
impair*')).ab.
8. ((convert or converted) adj4 (dement* or alzheimer* or AD or lewy or VaD or
'vascular cognit* impair*')).ab.
9. (progress* adj5 (dement* or alzheimer* or AD or VaD or lewy or 'vascular cognit*
impair*')).ab.
10. or/1-9
11. Prediction/ or Diagnosis/
12. (dement* or alzheimer* or AD or VaD or lewy or frontotemporal or 'vascular
cognit* impair*').ab.
13. exp *Dementia/
14. or/11-13
15. 10 or 14
16. exp Dementia/
17. exp Cognitive Impairment/
18. (alzheimer* or dement* or AD or lewy* or VaD or frontotemporal or 'vascular
cognit* impair*').ti,ab.
19. (forgetful* or confused or confusion).ti,ab.
20. MCI.ti,ab.
21. ACMI.ti,ab.
22. ARCD.ti,ab.
23. SMC.ti,ab.
24. CIND.ti,ab.
25. BSF.ti,ab.
26. AAMI.ti,ab.
27. LCD.ti,ab.
28. QD.ti,ab.
29. AACD.ti,ab.
30. MNCD.ti,ab.
31. MCD.ti,ab.
32. (nMCI or aMCI or mMCI).ti,ab.
33. ('N-MCI' or 'A-MCI' or 'M-MCI').ti,ab.
 
July
2012:
2645
Jan
2013:
464
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34. 'Petersen criteria'.ab.
35. ((CDR adj2 '0.5') or ('clinical dementia rating' adj3 '0.5')).ab.
36. (neurofibril* adj3 tangle*).ti,ab.
37. (neurofilament adj3 protein*).ti,ab.
38. (neuropil adj3 thread*).ti,ab.
39. ((senile or amyloid or neuritic) adj3 plaque*).ti,ab.
40. exp Neurofibrillary Tangles/
41. exp Senile Plaques/
42. or/16-41
43. (cerebrospinal fluid* or csf or 'spinal fluid*').ti,ab.
44. (blood or plasma).ti,ab.
45. exp Cerebrospinal Fluid/
46. exp Blood Brain Barrier/
47. or/43-46
48. tau.ti,ab.
49. hyperphosphorylation.ti,ab.
50. pTau181.ti,ab.
51. tau181.ti,ab.
52. ('abeta*/tau' and ratio).ab.
53. pTau*.ti,ab.
54. ('t-tau*' or 'p-tau*').ti,ab.
55. (innotest or inno-bia or Alzbio3).ti,ab.
56. ((abeta* or ab42 or ab40 or 'amyloid-beta' or 'beta-amyloid' or (amyloid and 'β')
or 'aβ' or 'aβ42' or 'aβ40' or 'a beta') adj4 ratio).ti,ab.
57. ('phospho-tau*' or 'total-tau*').ti,ab.
58. tau231.ti,ab.
59. or/48-58
60. 42 and 59
61. 47 and 60
62. 15 and 59
63. 61 or 62
4. BIOSIS Previews
(Thomson Reuters Web of
Science)
 
Topic = (tau OR p-tau OR t-tau OR pTau OR tTau OR hyperphosphorylation OR
pTau181 OR 'phospho-tau*' or 'total-tau*' OR tau231) AND Topic = (dement* OR
alzheimer* OR MCI OR 'cognit* impair*' OR 'CDR 0.5' OR 'petersen criteria' OR
aMCI OR nMCI OR mMCI) AND Topic = (diagnosis OR sensitiv* OR specificit* OR
ROC OR 'receiver operat*' OR 'Area under curve' or AUC OR sROC OR accura* OR
'follow*-up' OR 'positive predictive value*' OR 'negative predictive value*' OR
longitudinal OR longitudinally)
Timespan = All Years. Databases = BIOSIS Previews.
Lemmatization = On
 
July
2012:
1775
Jan
2013:
206
5. Web of Science Core
Collection, including
Conference Proceedings
Citation Index (Thomson
Reuters Web of Science)
(1945-present)
 
Topic = (tau OR p-tau OR t-tau OR pTau OR tTau OR hyperphosphorylation OR
pTau181 OR 'phospho-tau*' or 'total-tau*' OR tau231) AND Topic = (dement* OR
alzheimer* OR MCI OR 'cognit* impair*' OR 'CDR 0.5' OR 'petersen criteria' OR
aMCI OR nMCI OR mMCI) AND Topic = (diagnosis OR sensitiv* OR specificit* OR
ROC OR 'receiver operat*' OR 'Area under curve' or AUC OR sROC OR accura* OR
'follow*-up' OR 'positive predictive value*' OR 'negative predictive value*' OR
longitudinal OR longitudinally)
Timespan = All Years. Databases = Web of Science Core Collection.
Lemmatization = On
 
July
2012:
2205
Jan
2013:
234
DTA 19 CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias i...
83 / 89
 
Source
Search strategy Hits
retrieved
6. LILACS (BIREME) Hiperfosforilación OR hyperphosphorylation OR tau OR fosfo-tau OR phosphor-tau
OR p-tau OR pTau181 OR tau181 OR tau231
July
2012:
126
Jan
2013: 3
7. CINAHL (EBSCOhost) S1 TX dement*
S2 TX AD OR VaD OR lewy OR frontotemporal OR 'vascular cognit* impair*'
S3 TX alzheimer*
S4 (MH 'Dementia/DI')
S5 (MH 'Dementia/ET')
S6 TX 'conversion to' N2 dement*
S7 TX ('conversion from') N4 (dement* or alzheimer* or AD or lewy or VaD or
'vascular cognit* impair*')
S8 TX (endpoint* or 'end point*' or outcome*) N5 (dement* or alzheimer* or AD or
VaD or lewy)
S9 TX predict* N5 (dement* or alzheimer* or AD or VaD or lewy or 'vascular cognit*
impair*')
S10 TX (convert or converted) N4 (dement* or alzheimer* or AD or lewy or VaD or
'vascular cognit* impair*')
S11 TX progress* N5 (dement* or alzheimer* or AD or VaD or lewy or 'vascular
cognit* impair*')
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S13 (MH 'Predictive Value of Tests')
S14 TX dement* or alzheimer* or AD or VaD or lewy or frontotemporal or 'vascular
cognit* impair*'
S15 (MM 'Dementia+')
S16 S14 or S15
S17 S13 and S16
S18 S12 or S17
S19 (MH 'Dementia+')
S20 (MH 'Cognition Disorders')
S21 TX alzheimer* or dement* or AD or lewy* or VaD or frontotemporal or 'vascular
cognit* impair*'
S22 TX (cognit* or memory or cerebr* or mental*) N3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)
S23 TX forgetful* or confused or confusion
S24 TX MCI
S25 TX ACMI
S26 TX ARCD
S27 TX SMC
S28 TX CIND
S29 TX LCD
S30 TX AACD
S31 TX MNCD
S32 TX MCD
S33 TX nMCI or aMCI or mMCI
S34 TX 'N-MCI' or 'A-MCI' or 'M-MCI'
S35 TX 'Petersen criteria'
July
2012:
591
Jan
2013: 59
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S36 TX CDR N2 '0.5'
S37 TX 'clinical dementia rating' N3 '0.5'
S38 TX neurofibril* N3 tangle*
S39 TX neurofilament N3 protein*
S40 TX neuropil N3 thread*
S41 TX (senile or amyloid or neuritic) N3 plaque*
S42 S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or
S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41
S43 TX cerebrospinal fluid* or csf or 'spinal fluid*'
S44 (MH 'Cerebrospinal Fluid')
S45 S43 or S44
S46 TX tau
S47 TX hyperphosphorylation
S48 TX pTau181
S49 TX tau181
S50 TX (abeta* N3 tau) N4 ratio
S51 TX (amyloid* N3 tau) N4 ratio
S52 TX (ab42 N3 tau) N4 ratio
S53 TX (ab40 N3 tau) N4 ratio
S54 TX ('a beta' N3 tau) N4 ratio
S55 TX pTau*
S56 TX 't-tau*' or 'p-tau*'
S57 TX ('aβ40' or 'a beta') N4 ratio
S58 TX 'phospho-tau*' or 'total-tau*'
S59 TX tau231
S60 S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53 or S54 or S55 or S56 or
S57 or S58 or S59
S61 S42 and S60
S62 S12 and S60
S63 S17 and S45
S64 S61 or S62 or S63
TOTAL before de-duplication and first assessment  
July
2012:
18752
Jan
2013:
1694
2 Cross classification of test results and disease status (2X2)
Table 1: Conversion from MCI to Alzheimer’s disease dementia
Index test
information
Reference standard information
ADD present ADD absent
Index test positive Index test + who convert to ADD
(TP)
Index test + who remain MCI (FP) & Index test + who convert to non-
ADD (FP)
Index test negative Index test - who convert to ADD
(FN)
Index test - who remain MCI (TN) & Index test - who convert to non-
ADD (TN)
Table 2: Conversion from MCI to non-Alzheimer’s disease dementia
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Index test
information
Reference standard information
Non-ADD present Non-ADD absent
Index test positive Index test + who convert to non-ADD
(TP)
Index test + who remain MCI (FP) & Index test + who convert to
ADD (FP)
Index test negative Index test - who convert to non-ADD
(FN)
Index test - who remain MCI (TN) & Index test - who convert to
ADD (TN)
Table 3: Conversion from MCI to any form of dementia
Index test informationReference standard information
Any forms of dementia present Dementia absent
Index test positive Index test + who convert to any form of dementia (TP) Index test + who remain MCI (FP)
Index test negative Index test - who convert to any form of dementia (FN) Index test - who remain MCI (TN)
3 Assessment of methodological quality table QUADAS-2 tool
DOMAIN PARTICIPANT
SELECTION  
INDEX TEST  REFERENCE
STANDARD
FLOW AND TIMING 
Description Describe methods of
participant
selection: Describe
included participants (prior
testing, presentation,
intended use of index test,
and setting)
Describe the index
test and how it was
conducted and
interpreted
Describe the
reference standard
and how it was
conducted and
interpreted
Describe any participants who did
not receive the index test(s) and/or
reference standard or who were
excluded from the 2 x 2 table (refer
to flow diagram): Describe the time
interval and any interventions
between index test(s) and
reference standard
Signalling
questions:
(yes/no/unclear)
Was a consecutive or
random sample of
participants enrolled?
Were the index
test results
interpreted without
knowledge of the
results of the
reference
standard?
Is the reference
standard likely to
correctly classify the
target condition?
Was there an appropriate interval
between index test(s) and
reference standard?
Was a case-control design
avoided?
If a threshold was
used, was it
prespecified?
Were the reference
standard results
interpreted without
knowledge of the
results of the index
test?
Did all participants receive a
reference standard?
Did the study avoid
inappropriate exclusions?
Did all participants receive the
same reference standard?
Were all participants included in
the analysis?
Risk of bias:
High/low/unclear
Could the selection of
participants have
introduced bias?
Could the conduct
or interpretation of
the index test have
introduced
bias?      
Could the reference
standard, its
conduct, or its
interpretation have
introduced bias?
Could the patient flow have
introduced bias? 
Concerns
regarding
applicability:
High/low/unclear
Are there concerns that the
included participants do not
match the review question?
Are there concerns
that the index test,
its conduct, or
interpretation differ
from the review
question?
Are there concerns
that the target
condition as defined
by the reference
standard does not
match the review
question?
 
4 Anchoring statements for quality assessment of CSF tau and tau/ABeta ratio biomarkers diagnostic studies
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Category Review question Inclusion criteria
Participants Participants with mild cognitive
impairment, no dementia
Participants fulfilling the criteria for the clinical diagnosis of MCI at
baseline
Index test CSF t-tau; CSF p-tau;
CSF t-tau/ABeta ratio
CSF t-tau; CSF p-tau;
CSF t-tau/ABeta ratio
Target
condition
Alzheimer’s disease dementia
(conversion from MCI to Alzheimer’s
disease dementia)
Any other forms of dementia (conversion
from MCI to any other forms of dementia)
Alzheimer’s disease dementia (conversion from MCI to
Alzheimer’s disease dementia) 
Any other forms of dementia (conversion from MCI to any other
forms of dementia)
Reference
standard
NINCDS-ADRDA; DSM; ICD; McKeith
criteria; Lund criteria; NINDS-ARIEN
criteria
NINCDS-ADRDA; DSM; ICD; McKeith criteria; Lund criteria;
NINDS-ARIEN criteria
Outcome N/A Data to construct 2 X 2 table
Study design N/A Longitudinal cohort studies and nested case-control studies if they
incorporate a delayed verification design (case-control nested in
cohort studies)
Anchoring statements for quality assessment CSF tau and CSF tau/ABeta ratio
We provide some core anchoring statements for quality assessment of diagnostic test accuracy review of CSF tau and
CSF tau/ABeta ratio biomarkers in dementia. These statements are designed for use with the QUADAS-2 tool and are
based on the guidance for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia (Quinn 2014). 
During a two-day, multidisciplinary focus group and the piloting/validation of the guidance, it was clear that certain issues
were key to assessing quality, while other issues were important to record but less important for assessing overall quality. To
assist, we describe a 'weighting' system. Where an item is weighted 'high risk' then that section of the QUADAS-2 results
table is likely to be scored as 'high risk of bias'. For example, in dementia diagnostic test accuracy studies, ensuring that
clinicians performing dementia assessment are blinded to results of index test is fundamental. If this blinding was not
present, then the item on the reference standard should be scored 'high risk of bias', regardless of the other contributory
elements.
In assessing individual items, the score of 'unclear' should only be given if there is genuine uncertainty. In these situations,
review authors will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Patient selection
Was the sampling method appropriate?
Where sampling is used, the designs least likely to cause bias are consecutive sampling or random sampling. Sampling that
is based on volunteers or selecting subjects from a clinic or research resource is prone to bias.
Weighting: High risk of bias (‘no’)
Was a case-control or similar design avoided?
Designs similar to case-control that may introduce bias are those designs in which the study team deliberately increase or
decrease the proportion of subjects with the target condition, which may not be representative. For example, a population
study may be enriched with extra dementia subjects from a secondary care setting, who are typically more diseased. Some
case-control methods may already be excluded if they mix subjects from various settings.
Weighting: High risk of bias (‘no’)
Are exclusion criteria described and appropriate?
The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). Where
exclusions are detailed, the study will be graded as 'low risk' if exclusions are felt to be appropriate by the review
authors. Certain exclusions common to many studies of dementia are: medical instability; terminal disease;
alcohol/substance misuse; concomitant psychiatric diagnosis; other neurodegenerative condition. Exclusions are not felt to
be appropriate if ‘difficult to diagnose’ participants are excluded.
Post hoc and inappropriate exclusions will be labelled 'high risk' of bias.
Weighting: High risk (‘no’)
Index test
Was CSF tau and CSF tau/ABeta ratio biomarkers' assessment/interpretation performed without knowledge of clinical
dementia diagnosis?
Terms such as 'blinded' or 'independently and without knowledge of' are sufficient and full details of the blinding procedure
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are not required. Interpretation of the results of the index test may be influenced by knowledge of the results of reference
standard. If the index test is always interpreted prior to the reference standard, then the person interpreting the index test
cannot be aware of the results of the reference standard and so this item could be rated as ‘yes’.
For certain index tests the result is objective and knowledge of reference standard should not influence result, for example
level of protein in cerebrospinal fluid, in this instance the quality assessment may be 'low risk' even if blinding was not
achieved.
Weighting: High risk (‘no’)
Were CSF tau and CSF tau/ABeta ratio biomarkers’ thresholds prespecified?
For scales and biomarkers there is often a reference point (in units or categories) above which subjects are classified as 'test
positive'; this may be referred to as threshold; clinical cutoff or dichotomisation point. A study is classified 'high risk of bias' if
the authors define the optimal cut-off post-hoc based on their own study data because selecting the threshold to maximise
sensitivity and/specificity may lead to overoptimistic measures of test performance. 
Certain papers may use an alternative methodology for analysis that does not use thresholds and these papers should be
classified as not applicable.
Weighting: High risk (‘no’)
Reference standard
Is the assessment used for clinical diagnosis of dementia acceptable?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and
ICD-10. Criteria specific to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s
dementia; McKeith criteria for Lewy Body dementia; Lund criteria for frontotemporal dementias; and the NINDS-AIREN
criteria for vascular dementia. Where the criteria used for assessment is not familiar to the review authors or the Cochrane
Dementia and Cognitive Improvement group (‘unclear’), this item should be classified as 'high risk of bias'.
Weighting: High risk (‘no’)
Was clinical assessment for dementia performed without knowledge of the CSF tau and CSF tau/ABeta ratio biomarkers?
Terms such as 'blinded' or 'independently and without knowledge of' are sufficient and full details of the blinding procedure
are not required. Interpretation of the results of the reference standard may be influenced by knowledge of the results of
index test.
Weighting: High risk (‘no’)
Patient flow
Was there an appropriate interval between CSF tau and CSF tau/ABeta ratio biomarkers and clinical dementia assessment?
As we test the accuracy of the CSF tau and CSF tau/ABeta ratio biomarkers for MCI conversion to dementia, there will
always be a delay between the index test and the reference standard assessments. The time between reference standard
and index test will influence the accuracy ( Geslani 2005 ; Okello 2009 ; Visser 2006 ), and therefore we will note time as a
separate variable (both within and between studies) and will test its influence on the diagnostic accuracy. We have set a
minimum mean time to follow-up assessment of one year. If more than 16% of subjects of subjects have assessment for MCI
conversion before nine months this item will score ‘no’.
Weighting: High risk (‘no’)
Did all subjects get the same assessment for dementia regardless of CSF tau and CSF tau/ABeta ratio biomarkers?
There may be scenarios where subjects who score 'test positive' on index test have a more detailed assessment. Where
dementia assessment differs between subjects, this should be classified as 'high risk of bias'.
Weighting: High risk ('no')
Were all participants who received CSF tau and CSF tau/ABeta ratio biomarkers’ assessment included in the final analysis?
If the number of participants enrolled differs from the number of participants included in the 2 X 2 table, then there is the
potential for bias. If participants lost to dropout differ systematically from those who remain, then estimates of test
performance may differ.
If dropouts, these should be accounted for; a maximum proportion of dropouts to remain 'low risk of bias' has been specified
as 20%.
Weighting: High risk (‘no’)
Were missing or uninterpretable CSF tau and CSF tau/ABeta ratio biomarkers results reported?
Where missing or uninterpretable results are reported, and if there is substantial attrition (we have set an arbitrary value of
50% missing data); this should be scored as ‘no’. If those results are not reported, this should be scored as ‘unclear’ and
authors will be contacted.
Weighting: High risk (‘no’ and ‘unclear’)
Anchoring statements to assist with assessment for applicability
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Patient selection
Were included participants representative of the general population of interest?
The included participants should match the intended population as described in the review question. The review authors
should consider population in terms of: symptoms; pretesting; potential disease prevalence; setting.
If there is a clear ground for suspecting an unrepresentative spectrum the item should be rated 'poor applicability'.
Index test
Were sufficient data on CSF tau and CSF tau/ABeta ratio biomarkers’ application given for the test to be repeated in an
independent study?
Variation in technology, test execution, and test interpretation may affect estimate of accuracy. In addition, the
background, and training/expertise of the assessor should be reported and taken in consideration. If CSF tau and CSF
tau/ABeta ratio biomarkers were not performed consistently, this item should be rated 'poor applicability'.
Reference standard
Was clinical diagnosis of dementia made in a manner similar to current clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have assessed the dementia diagnosis.  For
certain reviews, an applicability statement relating to reference standard may not be applicable. There is the possibility that a
form of dementia assessment, although valid, may diagnose a far larger proportion of subjects with disease than usual
clinical practice. In this instance, the item should be rated 'poor applicability'.
Graphs
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